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ABSTRACT 
Metabolic syndrome (MetS) can classically be defined by physiological 
factors, clinical factors, and metabolic factors that are responsible for 
increased risk of cardiovascular diseases (CVD) and type 2 diabetes (T2D).  
The International Diabetes Federation has released the most recent definition 
of MetS, defined by increased waist circumference and two of the following 
factors:  increased serum triglycerides or decreased HDL-cholesterol, 
increased fasting blood glucose, or hypertension.  MetS is also profoundly 
defined by chronic low-grade inflammation.  This proinflammatory state can 
develop as a result adipocyte hypertrophy and hyperplasia that is responsible 
for increased secretion of glycerol, free fatty acids, and secretion of 
adipocytokines.  States of adipose tissue dysregulation due to obesity can 
directly affect systemic inflammation, and the progression to diseased states 
of insulin resistance and MetS.  Adipose tissue does not only contribute to the 
pathophysiology through proinflammatory signaling, but can alter systemic 
lipid content by releasing circulating free fatty acids (FFAs) that accumulate in 
liver, induce insulin resistance in skeletal muscle, and impair pancreatic β-cell 
functions, all contributing to the potential development of severe metabolic 
diseases.  Most importantly though, oxidative stress has been suggested to be 
an early event in the pathophysiology and manifestation of chronic metabolic 
disorders in humans including MetS, T2D, coronary artery disease, and 
hypertension.     
  
 The excess storage of lipids in white adipose tissue (WAT), known as 
obesity, results in oxidative stress and infiltration of macrophages that can 
alter WAT metabolism.  WAT is a metabolically active organ that is essential 
for proper maintenance of systemic energy balance.  WAT is a storage depot 
for triglycerides, and through hormonal-signaling is responsible for the release 
of energy to be utilized by tissues, such as, liver and skeletal muscle.  In 
addition to lipid metabolism and mobilization, WAT is responsible for glucose 
homeostasis, and has major endocrine functions involving secretion of 
hormones, cytokine, and transcription factors.  Due to the major functions of 
WAT, it is suggested that WAT plays an important role in the development of 
obesity-related diseases—requiring greater knowledge and understanding of 
WAT development, signaling pathways, and its role in systemic diseases.   
 As stated previously, oxidative stress is a unifying characteristic of 
factors that contribute to MetS, and it is well established that increased lipid 
content and metabolism can contribute to localized oxidative stress.  Metabolic 
stress within WAT can be defined as the balance between antioxidants and 
oxidative stress—and publications have begun to demonstrates its effects on 
adipose tissue, as it relates to metabolic diseases.  Another form of oxidative 
stress is achieved through the generation of reactive oxygen species (ROS) by 
environmental toxicants.  This form of chemical-induced oxidative stress can 
also be considered important in WAT due to the highly lipophilicity and 
deposition of persistent organic pollutants in adipose tissue, and the growing 
concern of these chemicals to act as obesogens.  Within this dissertation, 
  
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is addressed as a potential 
responsive transcription factor to both metabolic stress and nutrient status 
within a cell, and chemical-induced oxidative stress by persistent lipophilic 
environmental toxicants in WAT.   
 Nrf2 is a nuclear transcription factor that is known to regulate 
expression of antioxidant proteins in response to stimulation by oxidative 
stress or inflammation.  Nrf2 is still studied for its cytoprotective effects, but 
has recently been shown to regulate genes involved in lipid metabolism.  
Therefore, this overlap in the regulation of antioxidant response and lipid 
metabolism through antioxidant response element (ARE) activation provides a 
potential model for the interplay between oxidative stress and metabolic 
diseases. Our lab has been able to establish the importance of Nf2 in models 
of steatosis, calorie restriction in the liver, and most recently in obesity and 
adipogenesis.     
 The purpose of the study performed in MANUSCRIPT I is to elucidate 
the role of Nrf2 in calorie restriction and identify a potential mechanism of Nrf2-
dependent lipid regulation involved in weight loss and decreased fat storage.  
Few studies exist that have shown Nrf2 activation in adipose tissue (AT), and 
even fewer studies demonstrate the response of Nrf2 to nutrient status.  The 
data presented in this study demonstrate that 1) The ARE, Nrf2, and classical 
downstream target expression is induced by calorie restriction in WAT, 2) Nrf2 
induction bolsters the antioxidant capacity in vivo and in vitro, 3) Key 
regulators of calorie restriction and WAT lipid metabolism are induced by an 
  
Nrf2-dependent pathway, 4) Important enzymes involved in lipid uptake, 
lipogenesis, and lipolysis are Nrf2-dependent genes, and 5) CR mimetics and 
Nrf2 activators can decrease lipid content of adipocytes.     
In summary, MANUSCRIPT I, demonstrates the importance of increased 
antioxidant capacity to alleviate factors involved in the development of MetS, 
such as: glucose intolerance, hypertriglyceridemia, and obesity.  The most 
significant finding is the ability of Nrf2 to respond to the nutrient status of the 
organism in order to regulate signaling pathways related to energy storage 
and mobilization.   
Nrf2 has a novel role in its response it metabolic stressors, nutrient overload, 
or nutrient deprivation, but the classical activation of Nrf2 by chemical-induced 
oxidative stress can be reconsidered in understanding how environmental 
contribute to development of fat mass or obesity.  Many environmental 
toxicants are known to stimulate the ARE/Nrf2 signaling pathway, and it has 
been considered a hallmark of induction of oxidative stress.  Most recently 
though, environmental chemicals are more persistent in the environment and 
more lipophilic, therefore being deposited in lipophilic tissues such as AT.  The 
ability of these compounds to activate Nrf2 may not result in an antioxidant 
response, but can potentially alter the homeostasis of WAT and cause AT 
dysfunction.  AT dysfunction is the hallmark of many diseases, and can be 
directly to related to obesity.  In MANUSCRIPT II, 2,2',4,4',5-
pentabromodiphenyl ether (BDE-99) is studied for its ability to induce 
adipogenesis and lipid development in models of pre-adipocyte differentiation.  
  
The ability of the compound to act as an obesogen in WAT, allows for Nrf2 to 
be studied in a mechanism of chemical-induced regulation of lipid metabolism.  
Therefore, the purpose of MANUSCRIPT II, was to demonstrate that 
environmental toxicants can alter Nrf2 expression and subsequent oxidative 
stress response to alter lipid metabolism in WAT.  The observations in this 
study support 1) The role of BDE-99 in the development of excess lipids 
during adipocyte differentiation, and 2) A potential mechanism of decreased 
Nrf2-signaling during differentiation.   
To summarize, MANUSCRIPT II, demonstrates the ability of an environmental 
chemical to alter WAT metabolism and contribute to adiposity, through a 
potential Nrf2-dependent regulation of antioxidant capacity or lipid metabolism 
directly.   
Lastly, MANSCURPT III, studies the ability of perinatal deltamethrin exposure 
to alter WAT metabolism.  The focus of this study was to demonstrate that an 
environmental compound exposure during gestation and alter WAT 
metabolism and result in phenotypic changes.  The observations in the study 
demonstrate 1) Nrf2 can be induced by chemical-exposure in WAT, 2) 
Perinatal-exposure to deltamethrin has a hermetic effect on gene expression 
that does not result in phenotypic changes as adults, 3) Deltamethrin could 
epigenetically reprogram gene expression, and potentially be involved in the 
development of susceptibility to obesity or metabolic diseases related to WAT 
metabolism.   
  
In summary, MANUSCRIPT III, represents a perinatal exposure model in 
which Nrf2 is downregulated in WAT and results in a subsequent down-
regulation of genes involved adipogenesis, fat metabolism, and cytokine 
expression.   
In conclusion, this dissertation establishes a link between antioxidant 
response/oxidative stress and WAT metabolism through the ARE/Nrf2 
signaling pathway and continues to demonstrate that Nrf2 activation is a 
hormetic effect and the timing, disease model, and length or intensity of 
activation need to be considered in order to maintain homeostasis of the vital 
signaling pathways regulated by Nrf2.  
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PREFACE 
This dissertation was prepared in manuscript format according to the 
University of Rhode Island Graduate School guidelines. This dissertation 
consists of three manuscripts that satisfy the requirements of the department 
of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University 
of Rhode Island. 
MANUSCRIPT I: The role of Nrf2 activation via calorie restriction in white 
adipose tissue:  The cross-talk between antioxidant signaling and lipid 
metabolism. 
This manuscript has been prepared for submission to ‘Antioxidants & Redox 
Signaling’ as an original research communication. 
MANUSCRIPT II: BDE-99 increases lipid accumulation throughout 
differentiation in 3T3-L1 and human pre-adipocytes in vitro. 
This manuscript has been prepared for submission to ‘Toxicological Sciences’.  
MANUSCRIPT III: Effects of Developmental Deltamethrin Exposure on 
White Adipose Tissue Gene Expression. (J Biochem Mol Toxicol. 2013 
Apr;27(4):251-2.) 
This manuscript has been published in ‘Journal of Biochemical and Molecular 
Toxicology’.   
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Abstract 
Aim: The purpose of this study was to determine if calorie restriction (CR) 
contributes to an increased antioxidant capacity and to determine the role of 
Nrf2 activation in WAT; with specific focus on Nrf2-dependent and –
independent mechanisms in vivo, and AMPK and Nrf2 activation in vitro.  
Nuclear factor-E2 related-factor 2 (Nrf2) is a well-established inducible 
transcription factor resulting in transactivation of antioxidant response and 
cytoprotective genes.  CR, considered part of the primary management of 
metabolic syndrome by International Diabetes Federation (IDF), is defined as 
a total reduction in energy intake without nutrient deprivation.  Adipose tissue 
(AT) is an important endocrine organ that has recently been directly related to 
the pathophysiology of metabolic syndrome through altered metabolism and 
nutrient handling.  Oxidative stress has most recently been shown to be an 
important mediator of adipocyte dysfunction and dysfunctional adipose tissue.  
Therefore, this study addresses the importance of Nrf2 and antioxidant 
signaling in achieving homeostatic energy balance in white adipose tissue 
(WAT) in vivo and in vitro.    
Results: Data demonstrate that the antioxidant response element (ARE) and 
Nrf2 are inducible in WAT by calorie restriction. CR induction of antioxidant 
response is Nrf2-dependent, and Nrf2 contributes to signal transduction 
pathways related to adipocyte metabolism, specifically lipid metabolism. In 
WAT from ARE-hPAP mice, CR activated the ARE, and induced Nrf2 and 
downstream target gene expression.  Antioxidant capacity was Nrf2-
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dependent in WAT of female mice, and significant changes in protein 
expression of p-Ampk, Pparγ, and Lpl related to lipid metabolism were 
observed.  Lipogenesis and β-oxidation protein expression was not altered in 
Nrf2KO mice, but mRNA expression of Hsl, a lipolysis enzyme, was 
transcriptionally activated in WT-CR and not in Nrf2KO mouse model.   In vitro 
adipocyte models illustrate that CR mimetics and Nrf2 activators induce 
antioxidant gene expression, cytosolic antioxidant capacity, and decrease 
triglycerides.   
Innovation: This work illustrates mechanisms by which CR bolsters antioxidant 
capacity in the adipose tissue.  These findings establish the importance of 
Nrf2-mediated antioxidant response in CR and WAT metabolism.   
Conclusion: The current data support a novel role of nutrient status in the 
regulation of Nrf2 and the antioxidant response in WAT, and point toward  Nrf2 
as a factor to combat oxidative stress and regulate lipid metabolism in WAT.   
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INTRODUCTION 
Adipose tissue (AT) has been underestimated in its function to regulate 
metabolism and has been recently described as a vital endocrine organ.  AT is 
composed of adipocytes, pre-adipocytes, macrophages, and endothelial cells 
that are key components in the maintenance of systemic energy balance 
(Kusminski and Scherer, 2012).  AT is the primary organ for lipid storage in the 
form of triglycerides and release of free fatty acids (FFAs) to maintain energy 
homeostasis and respond to whole-body energetic needs (Rutkowski et al., 
2015); therefore, adipocytes have a higher burden of free-fatty acids (FFA) 
during normal physiological conditions compared to other cells (Kusminski and 
Scherer, 2012).  Due to this primary metabolic function of AT, adipocytes 
tolerate a high reactive oxygen species (ROS) load that cannot be sustained 
by other cells or organs without apoptosis (Kusminski and Scherer, 2012).  It 
has been discussed that the electron-transport chain (ETC) is the major 
producer of ROS in adipocytes, with the production of superoxide anion 
radicals (O2•
—) and downstream secondary messenger, hydrogen peroxide 
(H2O2) (Kusminski and Scherer, 2012). As reviewed by Kusminski, excess 
caloric-intake is characterized by increased ROS production by the ETC and 
an overload of oxidative stress associated with obesity(Kusminski and 
Scherer, 2012).  Increased oxidative stress associated with obesity leads to a 
dysfunctional antioxidant response, as demonstrated by a down-regulation of 
antioxidants such as, superoxide dismutase 2 (Sod2), glutathione peroxidase 
(GPx), catalase in mouse model of metabolic syndrome (Furukawa et al., 
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2004), and glutathione-S-transferase (GSTA4) in obese and insulin-resistant 
humans (Curtis et al., 2010). WAT is also known for its ability to expand, a 
function that is considered important in the protection against metabolic 
abnormalities (Kusminski and Scherer, 2012).  It has been demonstrated in 
vitro that moderate ROS can lead to hypertrophic adipocytes due to decreased 
expandability which is reversible by treatment with antioxidants; therefore, 
changes in oxidative metabolism may act as signals involved in determining 
lipid pool size and tissue mass in metabolic diseases (Carriere et al., 2003). 
Excess ROS production is considered in the pathophysiology of diseases, 
specifically metabolic syndrome, and changes in the antioxidant capacity of AT 
can be assessed in order to determine beneficial mechanisms to combat these 
diseases that are highly correlated to dysfunctional AT.       
Calorie restriction (CR) is considered part of the primary management of 
metabolic syndrome by International Diabetes Federation (IDF) and is defined 
as a total reduction in energy intake without nutrient deprivation.  Dietary 
intervention in humans is the most effective therapy to combat metabolic 
syndrome (Lopez-Legarrea et al., 2013).  The underlying mechanism of 
metabolic syndrome and an effective pharmacological target have not been 
identified in order to treat the disease as a whole.  The IDF has defined 
metabolic syndrome as an individual having central obesity and two of the four 
precursors to disease: dyslipidemia (increased triglycerides or lowered HDL-
cholesterol), insulin-resistance (increase fasting blood glucose), or 
hypertension (increased blood pressure).  Oxidative stress and dysfunctional 
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AT can be linked to each of these states in human studies (Bremer et al., 
2011;  Bremer and Jialal, 2013;  Furukawa, Fujita, Shimabukuro, Iwaki, 
Yamada, Nakajima, Nakayama, Makishima, Matsuda and Shimomura, 2004;  
Roberts and Sindhu, 2009;  Vincent and Taylor, 2006).  The RESMENA study, 
in which a novel dietary strategy was compared to the American Heart 
Association (AHA) guidelines for dietary components, revealed that dietary 
total antioxidant capacity (TAC) was the predominant factor in decreased body 
weight, BMI, and fat mass (Lopez-Legarrea, de la Iglesia, Abete, Bondia-Pons, 
Navas-Carretero, Forga, Martinez and Zulet, 2013).  Dietary TAC compared to 
other dietary aspects is most relevant to decrease in markers of obesity and 
metabolic syndrome (Abete et al., 2010;  Lopez-Legarrea, de la Iglesia, Abete, 
Bondia-Pons, Navas-Carretero, Forga, Martinez and Zulet, 2013;  Puchau et 
al., 2009). Therefore, understanding the mechanism by which CR maintains 
energy homeostasis in AT without production of excess ROS may be essential 
in determining an effective pharmacological treatment of metabolic syndrome.    
 CR has been shown to transcriptionally induce a battery of antioxidant 
genes in liver accompanied by Nrf2 expression, and this antioxidant response 
was attenuated in Nrf2KO mice (Pearson et al., 2008). Nrf2 was demonstrated 
to be inducible in WAT through Keap1-KD and pharmacological activators (Xu 
et al., 2012). The transcription factor has been classically defined to regulate 
the basal and inducible expression of genes, and is negatively regulated by 
Kelch-like ECH-associated protein 1 (Keap1) due to sequestration in the 
cytoplasm (Klaassen and Reisman, 2010;  Niture et al., 2010).  During periods 
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of cellular stress, by endogenous or exogenous increases in ROS and 
electrophiles, Nrf2 translocates to the nucleus, where it heterodimerizes with 
small Maf protein and activates the antioxidant response element (ARE) 
(Nguyen et al., 2009;  Niture, Kaspar, Shen and Jaiswal, 2010).  Activation of 
the ARE has been characterized to regulate genes involved in antioxidant 
response, and most notably Nrf2 is known to induce Phase I- and II- drug 
metabolizing enzymes and transporters for the elimination of potentially 
harmful xenobiotics (Klaassen and Reisman, 2010).  More recently, in both 
liver and WAT Nrf2 expression has been shown to be directly related to lipid 
content and body weight changes.  Our laboratory was able to show that 
constitutive activation of Nrf2 by Keap1-KD in vivo enhanced the reduction of 
liver triglycerides and non-esterified fatty acids (NEFAs) via CR by 
upregulation of β-oxidation genes (Kulkarni et al., 2013), and constitutive Nrf2 
activation also repressed HFD-induced obesity and lipid accumulation in WAT 
in vivo (Xu, Kulkarni, Donepudi, More and Slitt, 2012). A previous study 
showed that the prototypical Nrf2 activating compound, CDDO- Imidazolide, 
increased weight loss in HFD-mice (Shin et al., 2009).  There was also a 
positive relationship between hyperlipidemia and Nrf2 activation (Xu, Kulkarni, 
Donepudi, More and Slitt, 2012) suggesting that this well-described 
transcriptional regulator of the antioxidant response may have a potential role 
in the regulation of oxidative stress and lipid homeostasis in WAT.    
The purpose of this study was to identify whether 1) CR can induce the ARE 
and Nrf2-dependent gene expression in WAT, 2) WAT weight loss and lipid 
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homeostasis is Nrf2-dependent, and whether CR mimetics and Nrf2 activators 
can directly alter the antioxidant capacity of adipocytes to regulate WAT mass.  
Data presented herein describes CR induction of the Nrf2 pathway and 
antioxidant response in WAT, as well as the role of Nrf2 in decreased fat mass 
upon CR.   
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RESULTS 
CR induces the antioxidant response transcriptionally in WAT of mature 
ARE-hPAP mice, and Nrf2 induction is age-dependent.    The 40% CR was 
effective, as illustrated by a 36% loss of body weight (BW) (Fig. 1A), as well as 
WAT weight and 53.5 mg/dL decrease in blood glucose levels after 5 weeks of 
CR compared to ad libitum (AL) (Supplemental figure 1; Fig. 1B).  Induction of 
the ARE, measured by human alkaline phosphatase  (hPAP) expression, was 
only achieved in WAT (2-fold increase), whereas Nrf2 and downstream 
targets, Nqo1 and Gclc, were all induced greater than 2-fold in both WAT and 
skeletal muscle (SKM) (Fig. 1C).  For this CR paradigm, ARE-hPAP and Nrf2 
targets were not significantly altered (Fig 1C), although decreased liver weight 
was observed (Supplemental Figure 1).  Data from a second cohort of ARE-
hPAP mice separated by age, Mature (average age of 16-wks ± 25.5) versus 
Old (average age of 97-wks ± 16), illustrated that Nrf2 and Nrf2-target genes 
were inducible in the cohort of mature age, without induction of the ARE (Fig. 
2A), but not inducible by CR in old age even with induction of the ARE (Fig. 
2B).  The difference in expression and induction of genes may be due to large 
standard deviation in age of second cohort of mature ARE-hPAP mice.   
CR reduction in body weight and WAT is not Nrf2-dependent in both 
male and female mice.  To determine if Nrf2 is an integral signaling pathway 
in CR and if the reduction of WAT weight is Nrf2-dependent, male and female 
Nrf2KO mice were placed on a 40% and 25% calorie-restricted diet, 
respectively.  BW and WAT weight were measured.  In both male and female 
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Nrf2KO mice on CR, BW and WAT weights were not significantly different 
from wild-type (WT) mice CR (Fig . 3 A and 3B).  Ad libitum Nrf2KO mice have 
a decreased initial body weight and WAT weight compared to WT (Fig. 3B); 
these data are consistent with previous publications that demonstrate the 
importance of Nrf2 for adipocyte differentiation (Hou et al., 2012;  Pi et al., 
2010).  CR decreased body and WAT weight similarly in male and female WT 
and Nrf2KO mice CR increased Nrf2 and Nqo1 mRNA expression in WT, but 
not Nrf2KO WAT (Fig. 3B and 3C), which Nrf2 and Nqo1 gene expression in 
WT WAT was similar to that observed in the ARE-hPAP mice (Fig. 1C); with 
Nrf2 and Nqo1 expression being induced by at least 2-fold respectively (Fig. 
3C).       
 
CR induces the antioxidant response in WAT and serum antioxidant 
capacity in vivo.  CR doubled Gclc mRNA in WAT of both male and female 
mice, but not in Nrf2KO mice (Fig 4A), whereas catalase mRNA expression 
was increased similarly (2-3-fold) in both WT-CR and Nrf2KO-CR (Fig. 4B).  
Subsequently, serum antioxidant capacity (AOC) was measured by ORAC 
assay in order to assess whether CR bolstered the antioxidant capacity in 
WAT.  Male and female serum AOC was determined after 5 and 6 weeks of 
CR, respectively.  CR increased AOC in male and female WAT (Fig 5A and 
B), but this induction was only significantly Nrf2-depdendent in females, with 
AOC in Nrf2KO being similar to WT-AL fed females (Fig. 5B).       
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Sod1 increased protein and activity by calorie restriction in female mice 
is Nrf2-indepednent, and proposed to be a potential WAT factor in 
systemic glucose homeostasis and hepatic gluconeogenesis.  Induced 
oxidative stress in obese and diabetic mice has been shown to decrease Sod1 
in WAT (Furukawa, Fujita, Shimabukuro, Iwaki, Yamada, Nakajima, 
Nakayama, Makishima, Matsuda and Shimomura, 2004), and models of Sod1 
activation have decreased glucose intolerance and lipid peroxidation caused 
by HFD.  To determine whether Sod1 is regulated via Nrf2 upon CR and 
contributes to changes in systemic glucose metabolism: Sod1 mRNA, protein, 
and enzyme activity was measured. Glucose tolerance (GTT) and pyruvate 
tolerance tests (PTT) were carried out in WT and Nrf2KO mice.  Nrf2 was 
observed to contribute to an increase in Sod1 mRNA upon CR (Fig. 6A), but 
post-transcriptional changes may be responsible for significantly induced 
protein expression in both WT and Nrf2KO mice (Fig. 6B).  Lastly, CR induced 
the enzymatic activity of Sod1 in WT-CR and Nrf2KO-CR mice, supporting 
protein expression observations (Fig. 6C).  Blood glucose levels were 
measured throughout the study and there was no difference in response to CR 
in the absence of Nrf2, with no significant difference between WT-CR and 
Nrf2KO-CR blood glucose levels (Figure 6D).  Subsequently, CR increased 
glucose tolerance in WT mice, but Nrf2KO mice basally had significant 
increase glucose tolerance compared to WT-AL (Fig. 6E).  Hepatic 
gluconeogenesis was induced in both WT and Nrf2KO mice, as demonstrated 
by an increased pyruvate tolerance, and to the same extent (Fig. 6F).  
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Therefore, Sod1 was shown to be induced without Nrf2 activation, and 
beneficial effects on glucose metabolism were not dependent on Nrf2, 
suggesting a role of Sod1 in preventing oxidative stress that 
contributes to glucose intolerance and decreased gluconeogenesis in models 
of obesity.        
  
p-Ampk and Pparγ lipid regulation is dysregulated at the transcriptional 
and protein level in Nrf2KO mice in vivo altering transcriptional 
regulation of lipid uptake and lipolysis genes.   The major transcription 
factors of CR, p-Ampk, and adipogenesis and lipid metabolism, Pparγ, were 
measured to assess whether CR induced changes in AMP:ATP ratio and 
altered lipid metabolism are Nrf2-dependent.  Ampk activation by 
phosphorylation was shown to be Nrf2-dependent in both male and female 
mice, but only female WT mice had a significant induction in protein 
expression upon calorie restriction (Fig. 7B).  Both male and female mice 
demonstrated a significant increase in Pparγ with CR, but only female mice 
showed an Nrf2-dependent response (Fig. 7B).  Lpl and Cd36, involved in lipid 
uptake from the serum, did show consistent protein expression between male 
and female mice and Nrf2 regulation, except that both males and females did 
not show a significant increase in Lpl upon calorie restriction (Fig. 7B).  Protein 
expression of these key factors in lipid mobilization did not reflect their mRNA 
expression or transcriptional activation by Nrf2 (Fig. 7A).  Therefore, there may 
be alterations in post-transcriptional modifications or protein turnover in calorie 
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restriction and Nrf2KO model.  Lastly, Hsl transcriptional activation by CR was 
demonstrated to be Nrf2-dependent (Fig 8A).  This reflects another 
downstream target of Pparγ.         
 
Induction of β-oxidation genes is not Nrf2-dependent, while negative 
feed-back for induction of lipogenic enzymes is dysregulated in Nrf2KO 
mice.  Key enzymes involved in both lipogenesis and fatty acid β-oxidation 
were measured to further assess the physiological response of WAT to CR 
and potential role of Nrf2.  β-oxidation was not altered by Nrf2KO, as 
demonstrated by 2-fold or greater induction of transcriptional regulators, Pgc-
1α and Pparα, and enzymes involved in the initial steps of β-oxdiation, Acadm 
and Eehad (Fig 9C). Genes involved in lipogenesis were not consistently 
transcriptionally activated by Nrf2.  Srebp1c and Fas were induced in both 
WT- and Nrf2KO-CR mice by 7.3- and 6.5-fold and 9- and 8-fold, respectively 
(Fig. 9A).  Other key enzymes in lipogenesis in WAT, Acc-1 and Scd-1, were 
shown to be induced upon CR by 16- and 6.4-fold, but Nrf2 acts as a 
coactivator for their transcriptional activation as demonstrated by a 
significantly decreased induction in Nrf2KO-CR mice, 10.5- and 3.7-fold, 
respectively (Fig. 9A).  All mRNA expression was analyzed in female mouse 
models of CR, but Nrf2-coactivation of Acc upon CR was reflected at the 
protein level in both male and female mice (Fig. 9B).         
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Calorie restriction mimetic, AICAR, and Nrf2 activators, oltipraz and 
sulforaphane induce the antioxidant response in vitro and decrease lipid 
load of mature adipocytes.  Two well accepted models of differentiated 
mature adipocytes, 3T3-L1 pre-adipocytes and MEFs were used to study the 
effect of calorie restriction and Nrf2 activation in vitro.  AICAR and oltipraz 
induced Nrf2 and transcriptional expression of downstream genes Nqo1 and 
Gclc in mature 3T3-L1 pre-adipocytes, and sulforaphane induced only Nqo1 
significantly at the mRNA level (Fig10A).  In mature 3T3-L1 pre-adipocyte 
model mRNA expression correlated with induction of cellular antioxidant 
capacity and Nqo1 protein expression (Fig. 10B and 10C).  p-Ampk was 
induced by AICAR and oltipraz at 6 and 12 h post-treatment, and Nqo1 
remained induced (Fig. 10C).  Total AMPK was increased at 12 h and 24 h 
post-treatment (Supplemental Fig 3).  Sulforaphane induced both p-Ampk and 
Nqo1 at 6 h, but protein expression did not remain stable (Fig. 10C). RLU 
quantification of all blots was determined (n=1) and represented in 
Supplemental Figure 3, in addition to total Ampk and β-Actin blots as controls.   
All 3 treatments induced the Nrf2-dependent antioxidant response cascade; 
therefore, in order to study if Nrf2 activation contributes to decrease in lipid 
content of adipocytes the lipid profile of mature MEFs and 3T3-L1 pre-
adipocytes was examined.  Both models showed significant decrease in 
triglycerides with Ampk and Nrf2 activation.  Triglyceride concentration was 
decreased significantly in MEFs and 3T3-L1 model by Aicar, 28% and 39%, 
oltipraz  19% and 42.5%, and sulforaphane 38%, respectively (Fig. 11A).  In 
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preliminary MEF experiments Sirt1720, a calorie restriction mimetic through 
activation of Sirt1, showed no significant decrease in triglycerides (Fig. 11A).   
Total lipid content, measured by oil red o staining, was reduced with 48 h 
treatment of AICAR, oltipraz, and sulforaphane in 3T3-L1 pre-adipocytes (Fig 
11B).  
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DISCUSSION 
Nrf2 is a transcription factor historically studied for its cytoprotective effects, 
and has recently been demonstrated to be a nutrient responsive factor and a 
key regulatior of lipid metabolism.  In the present study Nrf2 was demonstrated 
to be transcriptionally induced in WAT by CR in vivo resulting in upregulation 
of antioxidant signaling.  Other studies have only demonstrated an increase in 
Nrf2 upon CR by measurement of Nrf2, Nqo1, and other downstream targets’ 
activation in liver (Fu and Klaassen, 2014;  Pearson, Lewis, Price, Chang, 
Perez, Cascajo, Tamashiro, Poosala, Csiszar, Ungvari, Kensler, Yamamoto, 
Egan, Longo, Ingram, Navas and de Cabo, 2008).  CR was demonstrated to 
induce Nrf2 activation in WAT by subsequent activation of the ARE, Nqo1 and 
Gclc; therefore, this study supports our laboratory’s findings that the 
ubiquitously expressed transcription factor responds to nutrient stimulus in 
multiple metabolically active tissues (Kulkarni, Armstrong and Slitt, 2013;  
Kulkarni et al., 2014;  Xu, Kulkarni, Donepudi, More and Slitt, 2012).  In 
addition, CR-activation of Nrf2 was demonstrated to be physiologically 
important in inducing total serum antioxidant capacity.  TAC in humans has 
been negatively correlated to increased central fat and obesity in both males 
and females, with reduced TAC by 5-7% and 6-10%, respectively, with 
females having a greater reduction in TAC (Chrysohoou et al., 2007).  
Therefore, more recent studies have focused on the effect of increased TAC 
through dietary interventions (Lopez-Legarrea, de la Iglesia, Abete, Bondia-
Pons, Navas-Carretero, Forga, Martinez and Zulet, 2013;  Puchau, Zulet, de 
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Echavarri, Hermsdorff and Martinez, 2009).  Specifically, dietary TAC intake 
was a major factor in body weight, waist circumference, and fat mass 
decreases in the REMENA-S study (Lopez-Legarrea, de la Iglesia, Abete, 
Bondia-Pons, Navas-Carretero, Forga, Martinez and Zulet, 2013).  The 
induction of Nrf2 in WAT by calorie restriction contributed to an overall 
systemic induction of TAC without correlation to increased weight loss in mice, 
which differs from human data. Further studies need to address localized TAC 
levels and the direct role of WAT regulation in systemic TAC.   
It is previously reported that oxidative stress is directly related to obesity, 
glucose intolerance, and insulin resistance—specifically superoxide anion 
radicals (O2•
—) are a common feature across models of insulin resistance 
(Hoehn et al., 2009) and decrease in WAT Sod1 is associated with murine 
models of severe obesity, hyperlipidemia, and insulin resistance(Furukawa, 
Fujita, Shimabukuro, Iwaki, Yamada, Nakajima, Nakayama, Makishima, 
Matsuda and Shimomura, 2004).  Also, WAT oxidative stress has been 
demonstrated to effect insulin resistance with alterations in ROS linked to 
changes in insulin sensitivity in 3T3-L1 preadiocytes (Kusminski and Scherer, 
2012).  In our study we were able to demonstrate that Nrf2 was not necessary 
to enhance glucose tolerance and hepatic gluconeogenesis, and Sod1 
induction, a major enzyme responsible in reducing cellular oxidative stress, 
was not Nrf2-dependent; therefore, it can be suggested that Sod1 may be a 
key enzyme in maintaining glucose homeostasis.  This notion is supported by 
previously published data that demonstrate: the deleterious effects of Sod1 on 
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glucose homeostasis and lipid metabolism (Wang et al., 2012), the beneficial 
effects of Sod1 overexpression to decrease glucose intolerance and lipid 
peroxidation caused by a high-fat diet (Liu et al., 2013), and the induction of 
Sod1 in ob/ob mice by rosiglitazone to ameliorate insulin insensitivity 
(Takazawa et al., 2009).  The post-transcriptional modification or alteration in 
protein degradation is noted in our study due to discrepancies between Nrf2 
transcriptional regulation of Sod1 and Sod1 protein and activity.  This 
observation should be further investigated as another study has demonstrated 
the same regulation of Sod1 in WAT by exercise training (Sakurai et al., 2009).   
CR and P-Ampk have been previously studied in the context of Ampk as an 
energy sensor of intracellular adenosine levels and is activated by increased in 
AMP:ATP or ADP:ATP levels that can be due to cellular stress, low nutrients, 
and prolonged exercise (Mihaylova and Shaw, 2011).  Ampk is responsible for 
regulating catabolic and anabolic pathways by phosphorylation of proteins and 
has been reviewed to regulate metabolic transcription factors or enzymes in 
fatty acid synthesis, inactivation of Srebp1 and ACC in liver, or lipolysis, HSL 
and ATGL in adipose, to restore ATP levels (Mihaylova and Shaw, 2011).  An 
activator of AMPK is AICAR, which mimics AMP binding to the Ampkγ 
subunits (Mihaylova and Shaw, 2011).  In the present study we were able to 
demonstrate that calorie restriction induced phosphorylation of Ampk in vivo, 
and p-Ampk was inducible by AICAR (6 hr exposure), oltipraz (12 hr 
exposure), and sulforaphane (24 hr) in vitro.  In vitro modeling in pre-
adipocytes demonstrated a potential cross-talk between Ampk activation and 
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Nrf2 activation, in which AICAR induced p-Ampk and Nqo1 at 6 and 12 hrs, 
and oltipraz subsequently induced Nqo1 prior to its induction of p-Ampk.  
Recent publications support a cross-talk between Ampk and Nrf2 in 
proinflammatory macrophages treated with an Ampk activator, in which the 
data demonstrate that Nrf2 activation is Ampk-dependent and the anti-
inflammatory effect of the Ampk activator is Nrf2-dependent (Mo et al., 2014).  
The data presented in vivo demonstrated that Ampk phosphorylation was not 
induced by calorie restriction in Nrf2KO mice in both sexes.  Therefore, the 
response to metabolic stressors in metabolically active tissues, specifically 
WAT in the present study, may be dependent on the cross-talk between Ampk 
and Nrf2.  Additional studies should be developed to determine which nutrient 
responsive factor is upstream in the signaling cascade or if they are 
coordinately regulated in states of metabolic stress.   
The study of key regulatory pathways in adipocyte metabolism of both male 
and female mice contributes to the understanding of the role of Nrf2 in lipid 
homeostasis and the relationship between oxidative stress and lipid 
metabolism.  In WAT transcriptional activation of Nrf2 is responsible for CR-
induction of Pparγ, a master regulator of adipogenesis and lipid metabolism.  
Pparγ maintains metabolic homeostasis in adipose tissue, in which it is 
predominately expressed, that systemically protects against lipid overload in 
alternate tissues and maintains a balanced secretion of adipocytokines, 
predominantly involved in systemic insulin sensitivity (Janani and Ranjitha 
Kumari, 2015).  Pparγ is known for its transcriptional regulation of Lpl and 
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Cd36, genes directly involved in the uptake of lipids from serum, and the 
regulation of genes in lipogenesis or the stimulation of storage of fatty acids in 
mature adipocytes and WAT expandability(Janani and Ranjitha Kumari, 2015). 
Our findings provide in vivo data through CR-induced Nrf2 activation that 
supports previous findings that Nrf2 activates the Pparγ promoter activity in 
vitro (Pi, Leung, Xue, Wang, Hou, Liu, Yehuda-Shnaidman, Lee, Lau, Kurtz 
and Chan, 2010).  Nrf2 was demonstrated to be involved in the transcriptional 
activation of both Lpl and Cd36, either independently or as a coactivator, 
respectively.   
In addition to Nrf2 regulation of Pparγ and Lpl, Hsl gene expression was 
dependent on CR-induced Nrf2 activation, and initial in vitro data support the 
role of Nrf2 activation on activation of lipolysis upon CR (data not presented, 
Supplemental Figure 2).   Nrf2 activation was also shown to contribute to the 
activation of key enzymes involved in lipid storage, Acc-1 and Scd-1, which 
demonstrate the role of Nrf2 activation in adipose tissue expandability.  Lastly, 
CR-induction of β-oxidation in adipocytes was not Nrf2-dependent, but it is 
well-established that Pgc1-α is a master regulator of cellular energy 
metabolism and under normal conditions has a low expression level in WAT, 
but with increased mitochondrial biogenesis and oxidative metabolism Pgc1-α 
activation may be the predominant activator of downstream β-oxidation gene 
expression (Liang and Ward, 2006).   Therefore, our models of CR and 
utilization of the Nrf2KO mouse model demonstrated not only the role of Nrf2 
in CR-induced changes in lipid uptake and lipolysis, but other potential key 
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regulators in WAT metabolism that are responsive to CR specifically related to 
oxidative metabolism.     
The study not only demonstrated CR-induced Nrf2 activation in vivo, but the 
ability of the CR mimetic AICAR and Nrf2 activators, oltipraz and 
sulforaphane, to increase cellular antioxidant capacity and decrease lipid 
content in two in vitro models of mature adipocytes.  The in vitro findings 
further support a direct interplay between oxidative stress or antioxidants and 
lipid metabolism.  As stated previously all compounds were able to activate 
both p-Ampk and Nqo1, with varying degrees of induction, and produce 
equivalent physiological effects as seen in our in vivo modeling of CR.  Our 
data specifically support previously published data that have demonstrated 
oltipraz, a small molecule activator of Nrf2, and sulforaphane, an organic 
phytochemical inhibitor of Nrf2 degradation, attenuates fat gain in high-fat diet 
fed mice (Yu et al., 2011) and inhibit lipid accumulation in MEFs (Xu, Kulkarni, 
Donepudi, More and Slitt, 2012), respectively.  These data further represent 
the concept that Nrf2 is protective in various cell types (liver, lung, GI tract, 
kidney, skin, neurons, and macrophages), and the ubiquitously expressed 
protein coordinately regulates not only ARE-driven gene expression, but cell 
type-specific protective genes, which results in a bolstered local and systemic 
defense system (Lee et al., 2005).           
Recent publications support our overall finding that Nrf2 is inducible in WAT 
and plays a pivotal role in adipocyte metabolism to alter systemic 
pathophysiology of disease models.  Specifically, global and adipose-specific 
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Nrf2 deficiency correlated to a reduction in WAT mass and suppression of pro-
lipogenic and inflammatory genes and proteins, but resulted in worsened 
characteristics of metabolic syndrome (Xue et al., 2013).  At the other 
extreme, constitutive Nrf2 activation in leptin-deficient mice also impaired lipid 
accumulation in adipocytes and resulted in worsened insulin resistance  and 
hepatic steatosis by, reduction in insulin-signaling molecules in adipose and 
increase gene expression of pro-lipogenic factors in liver (Xu, Kulkarni, 
Donepudi, More and Slitt, 2012). Our model demonstrated an overall 
beneficial effect of Nrf2 activation by calorie restriction to alleviate metabolic 
stress and contribute to decreased lipid storage in WAT and liver 
(Supplemental Figure 4).   The notion that the benefits of Nrf2 activation are 
hormetic (Maher and Yamamoto, 2010;  Taguchi et al., 2010) is equally 
supported by our findings and previous publications; therefore, making it a 
difficult systemic drug target in diseased states.  Overall, the study was able to 
show that tissue-specific regulation of Nrf2 in adipose tissue can be described 
as a mechanism to combat metabolic diseases associated with oxidative 
stress and excess lipids in the presence of a healthy leptin-axis, and identified 
the potential therapeutic benefit of Ampk and Nrf2 cross-talk.     
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INNOVATION 
The data presented show a novel role of Nrf2 in calorie restriction related to 
WAT metabolism, and further contribute to potential mechanisms related to 
recently published data supporting the beneficial effects of antioxidant-rich 
dietary components and the overall beneficial effects of induced antioxidant 
capacity in calorie restriction.  These novel findings can provide insight into 
future pharmacological targets for the underlying oxidative stress in multiple 
precursors of metabolic syndrome, and subsequent metabolic diseases.  The 
ability to induce the ARE and subsequent Nrf2 gene expression in WAT of 
ARE-hPAP mouse model has never been described.    
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MATERIALS AND METHODS 
Animals and treatments.    Three animal models were used for the following 
animal studies:  ARE-hPAP transgenic reported mice from Dr. Jeff Johnson’s 
laboratory (Johnson et al., 2008), C57Bl/6 (wild-type, WT) mice purchased 
from Charles River Laboratories (Frederick, MD), and Nrf2KO mice shared 
from Dr. Curtis D. Klaassen’s laboratory (University of Kansas Medical 
School).  All animal studies and procedures were carried out in accordance 
with and approved by the Institutional Animal Care and Use Committee at the 
University of Rhode Island.  Adult 16-week old (n=9) ARE-hPAP transgenic 
reporter mice, and adult 14-week old male and female C57Bl/6 (n=10, n=16) 
and Nrf2KO (n=15, n=22) mice were monitored for food intake for 2 weeks, 
and average daily calorie intake was determined based on consumption of 
normal chow—Harlan Teklad LM-485 Mouse/Rat Sterilizable Diet (Harlan 
Laboratories, Indianapolis, IN) for 1 week, followed by purified and nutrient-
rich chow—AIN-93G Growth Purified Diet (TestDiet, St. Louis, MO) during 
week 2. At 18 weeks and 16 weeks, respectively, ARE-hPAP and C57Bl/6 and 
Nrf2KO mice were separated equally into two groups: ad libitum and calorie 
restricted (40% of daily average calorie intake for males, and 25% for 
females).  Calorie restricted mice were fed AIN-93G Growth Purified Diet 
based upon food weight equivalent to initial calculated daily calorie intake.  All 
cohorts received 6.62-7.72 kCal/day during calorie restriction (Supplemental 
Figure 5).  All cohorts were maintained on experimental diets (ad libitum or 
calorie restricted) for 5 to 6 weeks prior to sacrifice.  Body weight (BW) was 
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measured weekly and blood glucose (BG) was measured every 2 weeks via 
tail vein bleed with Bayer® Contour glucometer and corresponding blood 
glucose test strips. Prior to necropsy BW and BG were measured, and at time 
of necropsy white adipose tissue (WAT) and liver weights were measured. All 
tissues collected (liver, WAT, and skeletal muscle) were snap frozen in liquid 
nitrogen and stored at -80°C.  
Glucose and Pyruvate Tolerance Tests (GTT and PTT).  After a 16-hr fast 
both male and female cohorts received an i.p. injection of 2 g/kg of glucose 
(Sigma-Aldrich, St Louis, MD) for the GTT.  Pyruvate was administered as an 
i.p, injection of 2 g/kg of sodium pyruvate (Sigma) following an 18-hr fast for 
both male and female cohorts.  Fasting blood glucose concentrations were 
taken prior to the injections and 15, 30, 60, and 120 minutes post-injection.  All 
glucose concentrations were measured via tail vein bleed using a Bayer® 
glucometer following IACUC protocol.   
Media, Reagents, and Chemicals.  Dulbecco's Modified Eagle Medium 
(DMEM) high glucose (4.5 g/L) with L-glutamine (Lonza), DMEM/F-12 (Gibco), 
Fetal Bovine Serum (FBS, Gibco), and penicillin-streptomycin (pen-strep) was 
purchased from ThermoFisher Scientific (Waltham, MA).  Oltipraz was 
purchased from LKT laboratories (#04578, St Paul, MN) and Sirt1720 is a 
Selleck Chemicals, LLC compound (#51129, Pittsburg, PA).  All other 
chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO): 
Dimethyl Sulfoxide (DMSO), 5-Aminoimidazole-4-carboxamide 1-β-D-
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ribofuranoside (AICAR), L-Sulforaphane, 3-isobutyl-1-methylxanthine (IBMX), 
Dexamethasone (DEX), human insulin solution, and Oil Red O, specifically.       
 
Primary mouse embryonic fibroblast (MEF) isolation, differentiation, and 
treatment.    Primary MEF isolation from ARE-hPAP mice and differentiation 
to mature adipocytes was performed as described (Xu et al., 2015).  Following 
differentiation, day 9 mature MEFs were treated with DMEM containing 10% 
FBS and 1% pen-strep supplemented with DMSO (0.1%), AICAR (500 μM), 
Oltipraz (100 μM), or Sirt1720 (10 μM) for 4 days with media changed 2 days 
post-treatment.  MEFs were analyzed for lipid development, lipid content, and 
mRNA expression.         
3T3-L1 pre-adipocyte cell culture, differentiation, and treatment.     Mouse 
3T3-L1 pre-adipocytes (ATCC® CL-173™) were obtained from American 
Type Culture Collection (ATCC, Manassas, VA) and were cultured following 
ATCC protocol utilizing.  3T3-L1 pre-adipocytes were induced and 
differentiated according to previously described protocol (Shin, Wakabayashi, 
Yates, Wakabayashi, Dolan, Aja, Liby, Sporn, Yamamoto and Kensler, 2009;  
Xu, Kulkarni, Donepudi, More and Slitt, 2012).  Briefly, 48 h post-confluent 
cells were induced by induction media (Maintenance media (DMEM, 10% 
FBS, and 1 % p/s) supplemented with 0.5 mM IBMX, 0.2 mM DEX, and 10 
μg/mL insulin) for 48 h and then differentiated only in the presence of insulin 
(10 ug/mL) for 6 days.  At day 8, cells are considered mature with the 
formation of lipid droplets and maintained in DMEM supplemented with 10 % 
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FBS, and 1% pen-strep (maintenance media).  Mature 3T3-L1 pre-adipocytes 
were treated at Day 8 with maintenance media supplemented with DMSO 
(0.1%), AICAR (500 μM), Oltipraz (100 μM), or Sulforaphane (10 μM) for 24 
and 48 h.   3T3-L1 pre-adipocytes were analyzed for lipid development, lipid 
content, mRNA and protein expression, and antioxidant capacity.   
Cellular Lipid Development—Oil Red O Staining.     Mature MEF and 3T3-
L1 pre-adipocytes were stained for lipid development in 12-well plates (n=3 
per treatment).  Following treatment the media was removed and cells were 
gently washed with PBS and fixed with 10% acetate-buffered formalin 
(ThermoFisher Scientific, Waltham, MA) for 1 h.  Oil Red O stock solution 
(0.6%) was prepared in 100% isopropanol.   Oil Red O working solution was 
made directly prior to staining by combining Oil Red O stock solution and  DI 
water 3:2 v/v, allowing the solution to sit for 10 mins, and then filtering the 
solution.  Following fixation, the cells were washed and stained with Oil Red O 
working solution for 15 mins.  The cells were then rinsed with water until the 
water rinsed clear.  Cells were stored and imaged in DI water.  Oil Red O 
images were taken at 20x magnification (EVOS, Life Technologies, Carlsbad, 
CA), and Oil Red O staining was quantified by ImageJ software (National 
Institute of Health) following the previous published protocol (Mehlem et al., 
2013). 
Lipid Isolation and Quantification—Triglycerides.     Triglyceride 
concentrations from MEF and 3T3-L1 cells were measured from 1 mL PBS 
lysates (6-well plates; n=3/group) collected after 48 h treatment.  200 μl of 
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lysate was transferred to 15 mL screw-capped tube containing 3.75 mL 
chloroform-methanol (2:1, v/v) solution.   Water (0.5 mL) was added and 
centrifuged at 3000 rpm for 5 min at room temperature.  The chloroform-
methanol layer containing lipids was transferred to glass tube and evaporated 
to dryness in a fume hood overnight.  The completely dried lipid residue was 
resuspended in 200 ul of 1% Triton X-100 in 100% ethanol.  Extracted lipids 
and serum were measured for triglyceride content using the microtiter protocol 
for Triglycerides GPO-Reagent Kit (Pointe Scientific, Canton, MI).   Briefly, 
standard and samples (3 μl) were run in triplicate on a 96-well plate by adding 
250 μl of reconstituted triglyceride reagent, and absorbance was read at 540 
nm on Spectramax M2 (Molecular Devices, Sunnyvale, CA).  Cellular 
triglyceride content was expressed as a ratio of triglyceride concentration 
(mg/dL) to total protein concentration (mg/dL) of lysates determined by DCTM 
Protein Assay (Bio-Rad Laboratories, Hercules, CA).        
Messenger RNA quantification.     Total RNA was isolated from tissues or 
cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following manufacturer 
protocol, and quantified following cDNA synthesis (Transcriptor First Strand 
cDNA Synthesis Kit) via LightCycler 480® SYBR Green I Master chemistry 
(Roche Applied Sciences, Indianapolis, IN).  All gene primers (Supplemental 
table 1) were utilized at a final concentration of 0.5 μM with a final 
concentration of cDNA template of 50-60 ng.     
Oxygen Radical Antioxidant Capacity Assay (ORAC).     Whole blood was 
collected at time of necropsy and incubated on ice for 2 h prior to 
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centrifugation at  8,000 xg at 4°C for .  Serum was collected and stored at -
80°C.  3T3-L1 cytosolic cellular fractions were collected from NE-PER Nuclear 
and Cytoplasmic Extraction Kit (ThermoFisher Scientific, Waltham, MA) 
following the manufacturer protocol.   Mouse serum and 3T3-L1 media and 
cytosolic cellular fractions were diluted 1:500 and 1:100, respectively. The 
ORAC assay protocol by BioTek®  (citation) was optimized for the 
Spectramax M2 (Molecular Devices, Sunnyvale, CA) using sensitivity=6 and 
bottom-reader for a 96-well clear-bottom plate. Trolox standards and samples 
were pipetted in replicate (25 μl) with 150 μl of 2 μM fluorescein and 
fluorescence (485nm, 528nm) was measured over 1 h every minute 
immediately following addition of  the radical generator 2,2'-Azobis(2-
amidinopropane) dihydrochloride (AAPH). The total AUC was calculated on 
GraphPad Prism Software (La Jolla, CA). 
Western blotting.    Western blots were used for identification and 
quantification of WAT and 3T3-L1 pre-adipocyte proteins from total cell lysates 
in RIPA buffer.  Protein was electrophoretically separated by SDS-
polyacrylamide gel electrophoresis. The gel was transblotted on PVDF 
membrane (Bio-Rad Laboratories, Hercules, CA) at 100 V for 1 h. The 
membrane was blocked for 1 h (room temperature) with 5% non-fat dry milk in 
tris-buffered saline with 0.1% Tween 20 (TBS-T). The membrane was then 
incubated with primary antibody in 5 % BSA in TBS-T at 4°C overnight.  After 
washing, the membrane was incubated with species-specific  HRP-conjugated 
secondary antibody for 1 h at room temperature. Specific antibody information 
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and conditions are provided in Supplemental Table 2.  The blots were 
incubated in Clarity™ Western ECL Blotting Substrate (Bio-Rad Laboratories, 
Hercules, CA) and were visualized using autoradiography film.  Protein bands 
were quantified using ImageJ (National Institute of Health) and all bands were 
normalized to corresponding β-Actin protein quantification.     
Statistical Significance.  Student’s T-test was performed to determined 
statistical significance between ARE-hPAP mice fed ad libitum or CR, unless 
otherwise stated (p<0.05*, p<0.01**, p<0.001***, p<0.0001****).  Statistical 
significance was determined between WT-AL, WT-CR, Nrf2KO-AL, and 
Nrf2KO-CR for both male and female cohorts by one-way ANOVA followed by 
Newman’s Keuls post-hoc test.  Each letter represents a statistically significant 
difference between all groups. For in vitro statistical analysis one-way ANOVA 
followed by Dunnett’s Test was performed to determine significant differences 
between control (DMSO) and treatments (p<0.05*, p<0.01**, p<0.001***, 
p<0.0001****), unless otherwise stated.  
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Figure Legends: 
Figure 1.  ARE and Nrf2-target genes are induced with weight loss via 
calorie restriction.  ARE-hPAP mice were fed ad libitum (n=4) or 40% 
calorically restricted (n=5) for 5 weeks.  A)  Body weight (g) was monitored 
weekly. B) Blood glucose (mg/dL) was measured via tail vein bleed using a 
Bayer® glucometer week 2,4 and 5.  C) All metabolically active tissues at time 
of necropsy were analyzed for mRNA expression via qPCR.  Significance was 
determined by Student t-tests between AL and CR cohorts (p<0.05*, 
p<0.01**).   
Figure 2.  Mouse ARE and Nrf2-target genes are not transcriptionally 
activated in old age.  Two cohorts of ARE-hPAP mice were fed either ad 
libitum or 40% calorically restricted: mature age mice had an average age of 
16 wks±25.5 and old age mice had an average age of 97 wks±16.  A) WAT 
from mature aged mice (n= ) and B) WAT from old age mice (n= ) were 
analyzed for mRNA expression via qPCR. Significance was determined by 
Student t-tests between AL and CR cohorts (p<0.05*, p<0.01**, p<0.001***).    
Figure 3.  Decreased body weight and WAT due to calorie restriction is 
not Nrf2-dependent.  Both C57Bl/6 and Nrf2KO 16-week old mice were fed 
ad libitum or 40% calorically restricted for 5 weeks (males) or 25% calorically 
restricted for 6 weeks (females).  A) Male and female body weights (g) were 
measured weekly. B) At time of necropsy male and female WAT weight was 
measured (g, 0.01) and C) mRNA expression of Nrf2 and Nqo1 was measured 
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via qPCR.  A one-way ANOVA followed by Newman-Keuls post-hoc was used 
to determine statistical significance between all groups within each separate 
cohort (male and female) (each letter represents a difference in significance, 
a-d).   
Figure 4.  Calorie restriction induces genes involved in antioxidant 
response in WAT.  Gclc and Catalase, important antioxidant enzymes, were 
measured in male and female mice fed ad libitum or calorically restricted 
(40%, and 25% CR, respectively) were measured by qPCR.  A) Gclc mRNA 
expression compared to WT-AL. B) Catalase mRNA expression compared to 
WT-AL.   Statistical significance was determined by One-way ANOVA followed 
by Newman Keuls post-hoc.  
Figure 5.  Serum total antioxidant capacity in both male and female mice 
calorically restricted.  Total antioxidant capacity was measured in serum of 
both (A) male and (B) female mice fed ad libitum or calorically restricted (40% 
and 25%, respectively) by ORAC assay and expressed as Trolox equivalents 
(μM) determined from standard curve of Trolox antioxidant capacity.  
Statistical significance was determined by one-way ANOVA followed by 
Newman Keuls post-hoc.     
Figure 6.  Nrf2 is not needed for the induction of WAT Sod1 protein and 
activity by calorie restriction in female mice.  WAT collected from the 
female cohort (ad libitum or 25% calorically restricted) was analyzed for mRNA 
expression, protein levels, and enzymatic activity of Sod1.  A) Sod1 mRNA 
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expression by qPCR was normalized to B2M and represented as fold-change 
compared to WT-AL B) Sod1 protein was determined in whole cell lysates by 
western blot and expressed as RLU normalized to Gapdh C) Sod1 activity was 
measured by a commercially available kit (Biovision, Milpitas, CA) and 
represented as the % inhibition of xanthine oxidase.  The sample absorbance 
was normalized to individual sample blanks and % inhibition was calculated 
according to kit protocol.  Induction of WAT Sod1 may directly contribute to 
decreased blood glucose levels, glucose tolerance, and hepatic 
gluconeogenesis.  Blood glucose concentrations were taken every 2-weeks 
and at time of necropsy and glucose tolerance test (GTT) was performed at 
week 4 and pyruvate tolerance test (PTT) was performed at week 5 of calorie 
restriction.  Blood samples were taken via tail vein bleed and glucose 
concentrations were measured by a Bayer® glucometer following IACUC 
protocol  D) Average blood glucose levels (mg/dL) are represented over the 
course of the study E) Glucose concentrations were taken prior to i.p. injection 
of 2g/kg glucose and 15, 30, 60, and 120 minutes post-injection to measure 
glucose tolerance F) Glucose concentrations were taken prior to i.p. injection 
of 2g/kg sodium pyruvate and 15, 30, 60, and 120 minutes post-injection to 
indirectly measure hepatic gluconeogenesis.  
Figure 7.  p-Ampk and Pparγ lipid regulation is dysregulated at the 
transcriptional and protein level in Nrf2KO mice in vivo altering 
transcriptional regulation of lipid uptake genes.  WAT from male and 
female mice fed ad libitum or calorically restricted were analyzed for mRNA 
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expression and protein levels to assess the role of CR and Nrf2 in p-Ampk, 
Pparγ, Lpl, and Cd36 expression.  A) Transcriptional regulation of Pparγ, Lpl, 
and Cd36 was determined by measurement of relative mRNA normalized to 
B2M expression, and represented by fold change compared to WT-AL. B) All 
proteins were visualized by western blot and quantified using ImageJ analysis.  
Quantification of protein was normalized to β-actin levels and expressed as 
RLU (n=3). Statistical significance was determined by one-way ANOVA 
followed by Newman Keuls post-hoc.      
Figure 8.  Nrf2-dependent induction of rate-limiting enzyme of lipolysis, 
hormone sensitive lipase (Hsl).   Hsl gene expression was measured in both 
male and female cohorts by qPCR to determine the transcriptional activation 
upon CR.   
Figure 9. Negative feedback for induction of lipogenic enzymes does not 
occur in Nrf2-KO mice, but β-oxidation genes are responsive in both 
cohorts.  (A) Lipogenic and (B) β-oxidation gene expression was measured in 
the female cohort via qPCR and represented as fold change compared to WT-
AL. (C) Both male and female protein expression of Acc was measured to 
confirm transcriptional regulation by Nrf2.  Average protein band intensity per 
group (n=3) are represented by RLU measurement in ImageJ and normalized 
to β-actin expression.   
Figure 10.  Nrf2 and downstream targets are inducible in cultured 
adipocytes resulting in increased antioxidant capacity.   3T3-L1 pre-
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adipocytes were differentiated to mature adipocytes and treated at Day 9 in 
the presence of AICAR (500 μM), Oltipraz (100 μM), and Sulforaphane (10 
μM) for 24 hr prior to isolation.  A)  mRNA expression of Nrf2, Nqo1, and Gclc 
was measured via qPCR (n=3) as fold change compared to WT-AL B) NE-
PER extraction was performed to obtain the cellular cytosolic fraction, and an 
ORAC assay was performed to measure total antioxidant capacity represented 
at Trolox equivalents (μM), determined from a Trolox standard curve. C)  p-
Ampk and Nqo1 protein was measured in whole cell lysate RIPA extractions at 
6 hr, 12 hr, and 24 hr to demonstrate time-dependent induction, and are 
represented by western blot.  Refer to Supplemental figure 3 for quantification 
and total AMPK and β-actin protein expression. 
Figure 11.  Nrf2 inducing agents decrease lipid content and in cultured 
adipocytes.  Mature 3T3-L1 pre-adipocytes and MEFs were treated with 
DMSO (0.1%), AICAR (500 μM), oltipraz (10 μM), sulforaphane (10 μM), and 
Sirt1720 (10 μM), Day 8-10 and Day 9-13, respectively.  A) Triglyceride 
concentration (mg triglyceride/ g protein) was determined following 48 h 
treatment and B) total neutral lipid content was visualized by Oil Red O 
staining after 24 and 48 h treatments. A Dunnett’s test was used to analyze 
significance of treatment compared to control (p<0.05*, p<0.0001****).       
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Supplemental Figure 1. Total tissue weights of ARE-hPAP mice fed ad 
libitum or CR.  WAT and liver tissue were collected at time of necropsy from 
ARE-hPAP mice fed ad libitum or 40% CR.  Accurate weights (0.00g) were 
obtained prior to snap freezing A)  Average WAT weight (g) B) Average liver 
weight (g).  Statistical significance was determined by Student’s T-test, 
p<0.001*** p<0.0001****.      
Supplemental Figure 2. Primary human mesenteric adipocytes treated with 
Ampk and Nrf2 activators demonstrated induced lipolysis ex vivo.  Primary 
human adipocytes were used to determine if treatment with chemical 
activators, used in in vitro CR studies, stimulated lipolysis.  Primary human 
adipocytes were isolated from the mesenteric depot from an individual donor 
and incubated in the presence of adenosine deaminase (ADA, Roche, 
Indianapolis, IN), phenylisopropyl adenosine (PIA) and a chemical activator of 
Ampk or Nrf2 (n=3/treatment of biological replicates).  ADA and PIA are used 
to standardize any variations in adenosine levels, and ADA (1 units/mL) + PIA 
(20nM) is considered basal lipolytic rate due to inhibition of adenosine. 
Positive control, isoproterenol (10-6 M), was performed alongside treatments 
for direct measurement of stimulated lipolytic rates.  Isoproterenol significantly 
stimulated lipolysis with an average glycerol release of 367.6 nM (p<0.0001).  
Glycerol release was measured in the presence of AICAR (500 μM), Oltipraz 
(100 μM), and Sulforaphane (10 μM) (n=9/treatment—biological replicates 
performed in triplicate).  Statistical significance was determined by one-way 
ANOVA followed by Dunnett’s Test (p<0.01** and p<0.0001****).        
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Supplemental Figure 3.  Protein expression was measured in 3T3-L1 pre-
adipocytes following 6, 12, and 24 hr exposures.  A) p-Ampk:AMPK and 
Nqo1 protein quantification via ImageJ (n=1) normalized to β-Actin B) Total 
Ampk levels quantified via ImageJ B) β-Actin and total Ampk levels 
represented via western blot.  
Supplemental Figure 4.  Decreased triglyceride content in liver due to 
calorie restriction.  Overall decrease in liver weights was measured, and the 
metabolically active tissue was analyzed for changes in lipid content due to 
40% calorie restriction in male and 25% calorie restriction in female cohorts for 
5-6 weeks.  A) Liver weights were measured at time of necropsy (0.00 g) prior 
to snap-freezing of tissue.  Lipid extraction was performed on liver PBS lysates 
to measure B) triglyceride (mg triglyceride / g tissue) content and C) Serum 
triglycerides were measured directly.     
Supplemental Figure 5.  Average daily calorie intake during calorie restriction 
in in vivo models.  Male ARE-hPAP and Male WT and Nrf2KO mice were 
subjected to a 40% calorically restricted diet.  Female WT and Nrf2KO mice 
were only subjected to a 25% calorically restricted diet, but their daily caloric 
intake was not significantly different from the male cohorts.  A) Food intake 
was measured by total feed weight consumed and converted into calorie 
intake (3.89 kcal/g—purified chow) and represented as average kcal/day.  B) 
Calorie intake per day during calorie restriction was determined by a 40% 
(males) or 25% (females) decrease in average total Kcal/day consumption.   
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Figure I-1. 
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Figure I-2. 
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Figure I-3. 
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Figure I-4. 
Figure I-5. 
 
 
 
 
 
46 
 
Figure I-6. 
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Figure I-7. 
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Figure I-8. 
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Figure I-9 
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  Figure I-10 
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Figure I-11.  
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Supplemental Figure I-1.  
 
Supplemental Figure I-2.  
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Supplemental Figure I-3. 
 
 
 
 
 
 
54 
 
Supplemental Figure I-4. 
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Supplemental Figure I-5. 
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Abstract 
Flame retardants, specifically polybrominated diphenyl ethers (PBDEs), are chemical 
compounds widely used for industrial purposes and household materials.  NHANES 
data indicates that nearly all Americans have trace amounts of PBDEs in serum, with 
even higher levels associated with occupational exposure (foam recyclers and carpet 
installers). PBDEs are known to bioaccumulate in the environment due to their 
lipophilicity and stability, and more importantly have been detected in human adipose 
tissue.  The present study examined whether the PBDE congener, BDE-99 (0.2 μM-
20 μM) enhances adipogenesis of pre-adipocyte cell models in vitro by increased lipid 
accumulation.  3T3-L1 mouse pre-adipocytes and human visceral pre-adipocytes 
were analyzed for increased lipid development.  The second most abundant 
congener found in human adipose tissue, BDE-99 (20 μM), increased chemically-
induced pre-adipocyte differentiation in both mouse and human in vitro models.     
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Introduction 
Polybrominated diphenyl ethers (PBDE) are a class of brominated flame retardants 
that were part of the largest marketed group of flame retardants in 2004 due to their 
effectiveness and low cost (Birnbaum and Staskal, 2004).    There are 209 congeners 
of PBDEs, with the most prevalent being BDE-47,-99,-100,-153, and -154 (Birnbaum 
and Staskal, 2004).  PBDEs are found in electronics, textiles, and polyurethane foam, 
with major routes of exposure being inhalation and ingestion through indoor air /dust, 
outdoor air, animal food, and aquatic biota world-wide (Hoppe and Carey, 2007).  
PentaBDE was a commercially used flame retardant that is predominantly found in 
polystyrene foams, accounting for 30% of the weight of the foam, and was essentially 
only used in the Americas (Birnbaum and Staskal, 2004).  Due to the lipophilic and 
highly stable nature of PBDEs, concern has grown over their bioaccumulation in the 
environment; as evidenced by their persistence in the environment via air/dust for 2 
days, water for 2 months, and soil for 6 months (Birnbaum and Staskal, 2004).   A 
remarkable decline in PBDE exposure has not been noted since initial bans of use of 
pentaBDE in 2008; which, could potentially be due to the persistence of the 
compounds in products prior to the ban, new products made from recycled materials, 
and continued presence in food sources (Tung et al., 2014).  PBDEs are detected in 
human adipose tissue, breast milk, birds, mammals, and fish (Hoppe and Carey, 
2007), and it is noted in a 2003-2004 study of a cohort in New York City that the BDE-
47 and BDE-99 were the most prevalent congeners found in human subcutaneous fat 
depots with a mean concentration of 399 ng/ g lipid weight (Johnson-Restrepo et al., 
2005).  BDE-99 has been shown to be a well absorbed congener, and therefore 
preferred sites of deposition are lipophilic tissues (Birnbaum and Staskal, 2004).           
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 The persistence of  PBDEs and their potential effects on the environment and 
human health has been brought to the forefront by the US EPA, who identified 
PBDEs a priority human health concern (Tung, Boudreau, Wade and Atlas, 2014).  
Due to the deposition of the most abundant congeners in WAT (BDE-47 > BDE-99 > 
BDE-100 > BDE -153) (Johnson-Restrepo, Kannan, Rapaport and Rodan, 2005) and 
the increased knowledge of interactions between persistent organic pollutants 
(POPs), predominantly endocrine disruptors, and adipose tissue (AT) (La Merrill et 
al., 2013), recent research has begun to focus on the effects of PBDEs on AT 
metabolism.  It has been well established that PBDEs act as endocrine disruptors by 
decreasing T4 levels or identified as agonists/antagonists of estrogen receptors 
(Hoppe and Carey, 2007).  
AT is metabolically active and essential for normal lipid homeostasis.  
Adipocytes can be stimulated by insulin to store excess energy in the form of 
triglycerides, and can release those stores by lipolysis to meet energetic needs during 
periods of metabolic stress (e.g. fasting and calorie restriction) (La Merrill, Emond, 
Kim, Antignac, Le Bizec, Clement, Birnbaum and Barouki, 2013).  Due to the nature 
of the composition of AT, persistent organic pollutants (POPs) can not only alter 
metabolic pathways in mature adipocytes, but can influence the differentiation of pre-
adipocytes.  Pre-adipocytes are fibroblasts within WAT that are induced through 
hormonal signals and a specific signal-transduction cascade to differentiate (Kamstra 
et al., 2014). The study of effects of POPs on the differentiation of pre-adipocytes is 
directly relevant to developmental models, insulin sensitivity, and obesity related to 
WAT metabolism.  Therefore, there are several publications that address BDE-47 
effects on pre-adipocyte differentiation (Kamstra, Hruba, Blumberg, Janesick, 
 
 
 
60 
 
Mandrup, Hamers and Legler, 2014), but none that address the second major 
congener BDE-99.   
 Oral administration of a BDE-47 and BDE-99 mixture to rats altered insulin 
signaling with an increase in isoproterenol-stimulated lipolysis and decrease in 
insulin-stimulated glucose oxidation that resembled metabolically obese and non-
insulin-dependent diabetic individuals (Hoppe and Carey, 2007).  Body burden of 
other BDEs are also implicated in the pathogenesis of diabetes and metabolic 
syndrome (Lim et al., 2008).  Therefore, studies using PBDE mixtures and the 
predominant congener BDE-47 for effects on adipogenesis have been of recent 
interest.  The mechanism by which PBDE mixtures enhance adipogenesis in WAT is 
not clear, and considering that the most prevalent congeners in human WAT are 
BDE-47, BDE-99, and BDE-153 (Johnson-Restrepo, Kannan, Rapaport and Rodan, 
2005), this paper focuses on determining the effect and mechanism by which BDE-99 
alone can contribute to an enhanced adipogenic effect.    
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Materials and Methods 
Chemicals and Reagents.  A neat 2,2',4,4',5-Pentabromodiphenyl ether preparation 
(BDE-99, catalog# ; lot# ) was purchased (AccuStandard®,Inc., New Haven, CT, and 
stock solution was prepared to 100 μM in DMSO.   Dulbecco's Modified Eagle 
Medium (DMEM) high glucose (4.5 g/L) with L-glutamine (Lonza), DMEM/F-12 
(Gibco), Fetal Bovine Serum (FBS, Gibco), and penicillin-streptomycin (pen-strep) 
was purchased from Thermo Fisher Scientific (Waltham, MA).  All other chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO): Dimethyl Sulfoxide (DMSO) , 3-
isobutyl-1-methylxanthine (IBMX), Dexamethasone (DEX), and human insulin 
solution, specifically.      
 
3T3-L1 pre-adipocyte cell culture, differentiation, and treatment.     Mouse 3T3-
L1 pre-adipocytes (ATCC® CL-173™) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA) and were cultured according to ATCC protocol.  
3T3-L1 pre-adipocytes (passage 6) were induced and differentiated according to a 
previously described protocol (Shin et al., 2009;  Xu et al., 2012).  Briefly, 48 h post-
confluent cells (day 0) were induced by induction media (DMEM, 10% FBS, IBMX, 
DEX, insulin (10 μg/mL)) for 48 h and then differentiated only in the presence of 
insulin (10 μg/mL) for 6 days.  Initial treatment of cells with vehicle (DMSO) or BDE-
99 (20 μM) was performed from Day 0-2 (induction) and Day 2-8 (post-induction).  All 
subsequent experiments, cells were treated with vehicle (DMSO) or BDE-99 (20 μM) 
throughout the course of differentiation, Day 0-8, and media was changed every 2 
days.     
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Human pre-adipocyte cell culture, differentiation, and treatment.   PoieticsTM 
human visceral pre-adipocytes (Cat #: PT-5005 Lot #: 0000313366, Lonza, 
Walkersville, MD) were passaged once and differentiated according to manufacturer’s 
instructions for use.  Cells were seeded at a density of 8700 cells/well in a 48-well 
plate using prepared Preadipocyte Growth Medium-2.  Treatment with BDE-99 (20 
μM) was carried out in the absence and presence of prepared Adipocyte 
Differentiation Medium (prepared media did not contain indomethacin) at day 0 and 
cells were stained for lipids or collected for mRNA analysis on day 11.   
 
Oil Red O Staining and Lipid Quantification.     3T3-L1 and human pre-adipocytes 
were stained for lipid development (n=3).  Cells were stained with Oil Red O at day 4, 
day 6, or day 8 following previously published protocol (Armstrong et al.).  Oil Red O 
images were taken at 10x magnification (EVOS, Life Technologies, Carlsbad, CA), 
and Oil Red O staining was quantified by isopropanol (100%) extraction followed by 
absorbance measured at 510 nm on Spectramax M2 (Molecular Devices, Sunnyvale, 
CA) and ImageJ software (National Institute of Health) following the previous 
published protocol (Mehlem et al., 2013).   
 
Western blot.    Western blots were used for identification and quantification of 3T3-
L1 pre-adipocyte proteins from total cell lysates in RIPA buffer.  Protein was 
electrophoretically separated by SDS-polyacrylamide gel electrophoresis.  Primary 
antibodies for Fatty Acid Synthase (C20G5) (Fas, #3180, Cell Signaling, Beverly, MA) 
and Fatty acid binding protein 4 (D25B3) (Fabp4, #3544, Cell Signaling) were 
prepared in 5 % BSA in TBS-T at a 1:3000 dilution and incubated at 4°C overnight.  
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Secondary antibody, anti-rabbit (Sigma-Aldrich) was carried out for 1 hr at room 
temperature.  The blots were incubated in Clarity™ Western ECL Blotting Substrate 
(Bio-Rad Laboratories, Hercules, CA) and visualized using autoradiography film.   
 
mRNA expression and quantification of Nrf2. Total RNA was isolated from tissues 
or cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following manufacturer 
protocol, and quantified following cDNA synthesis (Transcriptor First Strand cDNA 
Synthesis Kit) via LightCycler 480® SYBR Green I Master chemistry (Roche Applied 
Sciences, Indianapolis, IN).  All Nrf2 gene primers were utilized at a final 
concentration of 0.5 μM with a final concentration of cDNA template of 50-60 ng.      
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Results 
BDE-99 induces Fas and Fabp4 during induction (Day 0-2) and post-induction 
(Day 2-8) and demonstrated exposure during induction was not needed to 
induce lipid accumulation in pre-adipocytes.   3T3-L1 pre-adipocytes were 
induced in the presence of hormonal stimulators (DEX, IBMX, and insulin) with and 
without BDE-99, and pre-adipocytes were induced and were treated with or without 
BDE-99 during insulin-stimulated differentiation.   Fas and Fabp4 protein levels were 
observed to be induced during induction (Fig 2A), 3.6 and 6.6-fold, respectively 
(Supplemental Figure 1).  Only Fas was significantly induced (1.5-fold), by post-
induction treatment with BDE-99 (Fig. 2A and Supplemental Figure 1).  Increased 
Fabp4 protein during induction could signify increased fatty acid content prior to 
differentiation.  Quantification of western blots via ImageJ is shown in Supplemental 
Figure 1.  Post-induction BDE-99 treatment, in the presence of insulin, stimulated 
increased lipid development without chemical exposure during hormonal induction 
(Fig 2B and 2C), suggesting a direct involvement in the regulation of WAT 
lipogenesis.   
BDE-99 increases lipid development in differentiating pre-adipocytes.  3T3-L1 
pre-adipocytes were differentiated to mature adipocytes with or without BDE-99 for 6 
and 8 days.  Oil red O staining was utilized to assess lipid accumulation in maturing 
adipocytes.  Figure 3A, demonstrates that BDE-99 increases lipid content during 
differentiation compared to vehicle (DMSO), and when quantified both day 6 and 8 
have a significant increase in Oil Red O staining (Figure 3B).  An increase in lipid 
staining compared to DMSO was similar in both 2 and 20 μM treatments (Figure 4A).  
Quantification of the dose-dependent changes in lipid development revealed 
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increased in lipid staining for cells treated with 2 and 20 μM BDE-99, but not 0.2 μM.  
The induction was not concentration dependent (Figure 4B).   
BDE-99 treatment increases lipid development in human visceral pre-
adipocytes during differentiation.  In order to determine whether BDE-99 also has 
effects in human derived-cells we determined whether BDE-99 treatment increased 
lipid development using human visceral pre-adipocytes.  Human visceral pre-
adipocytes (Lonza) were treated with vehicle or BDE-99 (20 μM) in the absence or 
presence of differentiation media.  Figure 5A illustrates that lipid development is 
enhanced in both non-differentiated and differentiated pre-adipocytes, as depicted by 
an increase in Oil Red O staining with BDE-99 treatment compared to DMSO.  
Staining was quantified by Oil Red O absorbance and a significant increase of 
staining was shown in both non-differentiated and differentiated cells (Figure 5B); 
staining was further confirmed by ImageJ quantification of images of Oil Red O 
staining in which differentiated cells had a 1.9-fold increase and non-differentiated 
cells had a greater 2.7-fold increase in total lipid content (Figure 5C).               
BDE-99 decreases Nrf2 expression during adipogenesis.  Nrf2 gene expression is 
increased throughout the course of adipocyte differentiation, and BDE-99 (20 μM) 
decreases the basal level expression of Nrf2 throughout the course of differentiation 
(Figure 6).  Therefore, BDE-99 may not be acting directly on key pathways of 
adipogenesis, but may alter expression of Nrf2 that has previously shown to be 
important in adipocyte differentiation in mouse embryonic fibroblasts (Pi et al., 2010).     
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Discussion  
PBDEs have been identified as a primary human health concern by the U.S. 
EPA.  PBDEs have been shown to have toxicity potential in in vivo models, including 
altered thyroid hormone levels and morphological effects in thyroid, liver and kidney 
(Kalantzi et al., 2011), and non-Hodgkin’s lymphoma (Kalantzi, Geens, Covaci and 
Siskos, 2011) and metabolic syndrome  (Lim, Lee and Jacobs, 2008) have been 
associated with PBDE exposure in humans.  These observations are even more 
concerning, as measurements of PBDE levels were assessed in the human 
population over the last decade (Johnson-Restrepo, Kannan, Rapaport and Rodan, 
2005;  Malarvannan et al., 2013;  Sjodin et al., 2008;  Stapleton et al., 2008) with 
increasing exposures noted and persistence/bioaccumulation of compounds in the 
environment (Birnbaum and Staskal, 2004).  Human levels of PBDEs and specific 
congeners are not consistent across all studies.  PBDE exposure differs between 
populations, specifically concentrations of PBDEs in human matrices of European 
populations, exhibited lower exposure levels than U.S. populations predominantly due 
to the decreased usage of BFRs in these countries (Malarvannan, Dirinck, Dirtu, 
Pereira-Fernandes, Neels, Jorens, Gaal, Blust and Covaci, 2013).  Not only do 
exposure levels differ, but U.S. populations have demonstrated a difference in 
distribution of PBDE congeners (Kalantzi, Geens, Covaci and Siskos, 2011).  
PentaBDE is a mixture that is predominantly used in the United States and is 
composed primarily of tri- and hepta-BDEs(Kalantzi, Geens, Covaci and Siskos, 
2011); therefore, research within the U.S. has focused on congeners BDE-47 and 
BDE-99 due to population and environmental levels.  Our findings utilizing BDE-99 
predominately represent exposure specific to the U.S. population by exposure to 
pentaBDE (Kalantzi, Geens, Covaci and Siskos, 2011).    
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BDE-47 has been demonstrated to induce adipogenesis in models of 3T3-L1 
pre-adipocyte differentiation (Kamstra, Hruba, Blumberg, Janesick, Mandrup, Hamers 
and Legler, 2014;  Tung, Boudreau, Wade and Atlas, 2014), but the mechanism of 
action of BDEs needs to be studied further.  A mixture of PBDEs representative of the 
North American body burden and BDE-47 alone were shown to have dose-dependent 
increased in aP2 and perilipin protein and significant increase in mRNA expression by 
day 8, which is representative of increased lipid droplet size and development 
demonstrated through increased lipid accumulation by both treatments (Tung, 
Boudreau, Wade and Atlas, 2014).  This supports our observations that the congener 
BDE-99 also contributes to increased lipid development in differentiating pre-
adipocytes.  The findings also demonstrate that exposure during initial induction of 
pre-adipocytes is not needed to increase total lipid staining, as was previously shown 
with modest changes to mRNA expression during the first 2 days of differentiation 
(Kamstra, Hruba, Blumberg, Janesick, Mandrup, Hamers and Legler, 2014).   
An interesting finding and contribution to understanding the mechanism of 
BDE-induced adipocyte differentiation and lipid accumulation was BDE-47 and BDE-
99 have poor Pparγ binding activity determined by their relative potency (determined 
from IC50 and Kd values) (Fang et al., 2015).  The only active ligands of Pparγ were 
hydroxylated metabolites of BDE-47, and 5-OH-BDE-99 (Kd=30 μM)(Fang, Webster, 
Ferguson and Stapleton, 2015).  Therefore, no significant induction of Pparγ 
transcript by BDE-47 (Tung, Boudreau, Wade and Atlas, 2014), and induction of 
Pparγ2 mRNA without down-stream target gene expression (Kamstra, Hruba, 
Blumberg, Janesick, Mandrup, Hamers and Legler, 2014)  in 3T3-L1 cells 
demonstrates that Pparγ activation may not be the predominant transcription factor 
involved in induction of lipid development.  Preliminary studies of Pparγ protein 
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expression showed that the transcription factor was not up-regulated in our exposure 
model, but the γ2-subunit was induced with treatment without Cepbα induction 
(Supplemental Figure 2).  Interestingly, Pparγ expression was significantly increased 
by Day 8 by a PBDE mixture (Tung, Boudreau, Wade and Atlas, 2014), suggesting 
other potential congeners or metabolites are involved in its regulation.  Our 
subsequent finding of decreased Nrf2 expression with BDE-99 treatment supports a 
potential hypothesis of decreased adipogenesis with increased lipid development, 
resulting in hypertrophic adipocyte development.  It has previously been 
demonstrated that Nrf2KO MEFs have decreased ability to differentiate (Pi, Leung, 
Xue, Wang, Hou, Liu, Yehuda-Shnaidman, Lee, Lau, Kurtz and Chan, 2010), and 
without Pparγ and Cebpα induction, BDE-99 does not contribute to increased 
differentiation.  Therefore, further studies must be carried out to determine what 
lipogeneic pathway is targeted by BDE-99 treatment to increase lipid development 
throughout differentiation.      
BDE-99 was studied due to its prevalence in human adipose tissue, and more 
specifically because of its defined metabolism and disposition in rat and mouse 
models (Chen et al., 2006).  Chen et al. demonstrated that 85% of BDE-99 was 
absorbed by single-p.o. and 34-38% remained in tissues, with significant disposition 
in adipose and minimal decay of levels over 10 days, and significant increase in 
concentration with 10-day daily doses (Chen, Lebetkin, Sanders and Burka, 2006).  In 
addition to concentrated exposure of BDE-99 exposure in adipose tissue, it was 
demonstrated that BDE-99 was also more extensively metabolized than BDE-47, 
which is excreted by day 10 (Chen, Lebetkin, Sanders and Burka, 2006).  Therefore, 
the effect of BDE-99 exposure on adipose tissue is an essential to understand 
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potential human health outcomes, in which BDE-99 metabolites may need to be 
addressed for their toxicity also.   
Our study is the first to translate BDE-99 effect on adipogenesis and lipid 
development to a human model.  The findings support that human pre-adipocytes 
develop increased lipid development upon BDE-99 exposure in both non-
differentiated cells, and differentiating cells.  This research provides additional data 
supporting the understanding of POP exposure to cause dysregulation of insulin 
homeostasis, obesity, and hepatic steatosis,(Ruzzin et al., 2010) and the toxicological 
importance of adipose tissue (La Merrill, Emond, Kim, Antignac, Le Bizec, Clement, 
Birnbaum and Barouki, 2013).  Therefore, these human in vitro data can be utilized in 
order to determine if increased BDE-99 concentrations in adipose tissue contribute to 
insulin resistance, diabetes, obesity, and overall metabolic syndrome, with a 
mechanistic approach.           
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Figure 1.  In vitro pre-adipocyte differentiation paradigm with treatment of 
environmental toxicant BDE-99.  
Figure 2. BDE-99 induces Fas and Fabp4 during induction (Day 0-2) and post-
induction (Day 2-8) and it was demonstrated that exposure during induction of 
pre-adipocytes was not needed to induce lipid accumulation. 3T3-L1 pre-
adipocytes were treated with BDE-99 (20 μM) during induction (Day 0-2) and post-
induction (Day 2-8).  A)  Induced and post-induction pre-adipocytes treated with BDE-
99 were lysed in RIPA buffer and Fas and Fabp4 protein levels were determined by 
western blot B)  Post-induced pre-adipocytes were stained with Oil Red O, images 
were taken at 10x magnification C)  Images were quantified using ImageJ to 
determine induction of lipid content (n=2/treatment).        
Figure 3.  Increased lipid development throughout differentiation of 3T3-L1 pre-
adipocytes treated with BDE-99.  3T3-L1 cells were differentiated in the presence of 
DMSO (0.1%, control) or BDE-99 (20 μM).  A) Treated 3T3-L1 cells were stained for 
the development of neutral lipids by Oil Red O at Day 6 and Day 8. B) BDE-99 
dependent lipid development was determined through quantification of 5 separate Oil 
Red O images taken at 10x magnification per well (n=3 wells/treatment group).  
Significance was determined by individual Student’s t-test compared to control at 
each time point (p<0.01**, p<0.0001****).   
Figure 4.  Lower doses of BDE-99 in vitro elicit the same enhancement of lipid 
development in 3T3-L1 pre-adipocytes.  3T3-L1 cells were differentiated in the 
presence of DMSO (0.1%, control) or BDE-99 (0.2, 2, or 20 μM).  A)  Treated 3T3-L1 
cells were stained with Oil Red O at Day 8. B) Enhancement of lipid development 
during differentiation was quantified by ImageJ utilizing 5 separate Oil Red O images 
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taken at 10x magnification per well (n=3 wells/treatment group).  A Dunnett’s test was 
used to determined significance compared to control (p<0.01**, p<0.001***).    
 Figure 5.  Human visceral pre-adipocytes responded to BDE-99 treatment 
equally, with increased lipid content in mature adipocytes.  Human visceral pre-
adipocytes were treated with BDE-99 (20 μM) with and without Adipocyte 
Differentiation Media (ADM) for 11 days.  A)  Cells were stained with Oil Red O on 
Day 11 for the accumulation of neutral lipids in matured adipocytes and images were 
taken at 10x, 20x (not shown), and 40x magnification (EVOS, Life Technologies). B) 
Oil Red O was abstracted from the fixed cells with 100% isopropanol, and 
absorbance of each well was measured at 510 nm to quantify lipid staining.  C)  
ImageJ software was utilized to quantify 5 images from each well (n=3 
wells/treatment group) to confirm quantification of Oil Red O staining.  Significance 
was determined by Student’s t-test compared to control for both non-differentiated 
and differentiated staining (p<0.05*, p<0.01**).    
Figure 6. BDE-99 decreases transcriptional expression of Nrf2 throughout 
differentiation.  3T3-L1 cells were treated with DMSO (0.1%, control) or BDE-99 
(20 μM) from Day 0 to Day 8 of differentiation, and total RNA was collected at 
Day 4, Day 6, and Day 8.  Nrf2 mRNA expression was quantified via qPCR 
and normalized to housekeeping gene B2M.   Student’s T-test was used to 
determine the statistical significance between treatments for each individual 
time point (p<0.05*).   
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Supplemental Figure 1.  Quantification of Fas and Fabp4.  Fas and Fabp4 
were measured to assess the lipogenic pathway in BDE-99-treated 3T3-L1 
cells and fatty acid content.  Band intensity of each protein was measured via 
ImageJ (n=1).  Fas and Fabp4 protein was normalized to β-Actin, and 
expressed as Relative Luminescence Units (RLU).   
Supplemental Figure 2.  Protein detection of adipogenic transcription 
factors in BDE-99-treated 3T3-L1 cells.  3T3-L1 cells were exposed to 20 
μM BDE-99 during day 0-2 and day 2-8 of adipocyte differentiation, and whole 
cell lysates were obtained via RIPA extraction. A) Western blots of Pparγ and 
Cebpα.   
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
Figure II-1. 
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Figure II-2.  
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Figure II-3. 
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Figure II-4. 
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Figure II-5.  
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Figure II-6.  
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Supplemental Figure II-1. 
 
Supplemental Figure II-1. 
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ABSTRACT 
Deltamethrin, a type II pyrethroid, is a widely used insecticide.  The purpose of 
this study was to determine whether perinatal deltamethrin exposure altered 
the expression of adipogenic and lipogenic genes in white adipose tissue 
(WAT) in adult pups.  C57BL/6 pregnant mice were administered 0, 1, or 3 
mg/kg of deltamethrin orally every 3 days throughout gestation and lactation.  
Offspring were weaned on postnatal day 25 and WAT was collected from 5 
month old male mice.  Perinatal deltamethrin exposure decreased the mRNA 
expression of adipogenesis related transcription factors Pparγ, Cebpα and 
lipogenic genes Srebp1c, Acc-1, Cd36, Lpl, Scd-1; along with Nrf2 and target 
genes Nqo1 and Gclc at the 1 mg/kg treatment.  Cytokine expression of 
Fas/Tnf-R and Cd209e at the 1 mg/kg treatment was significantly decreased 
and expression of Tnf, Cd11c, and Fas/Tnf-R was decreased at the 3 mg/kg 
treatment.  Developmental deltamethrin exposure did not overtly affect body 
weight or adipose weight, but decreased mRNA expression of specific genes 
that may potentially disrupt normal adipogenesis and lipid and glucose 
metabolism if the offspring are challenged by changes in diet or environment.  
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INTRODUCTION  
Pyrethroids are synthetic chemicals modeled after the naturally 
occurring pyrethrins, found in chrysanthemums (1).  Type I and type II 
pyrethroids are commonly used as potent and effective insecticides for 
agricultural and public health applications (2) and can easily enter the 
exoskeleton of insects. These axonic poisons cause paralysis, and ultimately 
death of the organism by keeping sodium channels open in the neuronal 
membranes. Type II pyrethroids, such as deltamethrin, are defined by an α-
cyano group that is known to produce a longer-lasting inhibition of voltage-
activated sodium channels (1,2).  Pyrethroid pesticides are often thought of as 
“safer” alternatives to the more toxic organophosphates because of their low 
mammalian toxicity. This relatively low toxicity is attributed to a combination of 
efficient detoxification mechanisms in mammals (3) and lower sensitivity of ion 
channels (2). However, metabolic detoxification mechanisms are not fully 
developed in the very young, potentially increasing susceptibility to pyrethroids 
in this population (4). This is particularly crucial because pyrethroid use has 
increased tremendously since the cancellation or reduction in the use of many 
organophosphorus pesticides (5).  In recent years, significant levels of 
pyrethroid metabolites, including those of deltamethrin, have been found in the 
urine of pregnant women and children (6-9).  Furthermore, deltamethrin, which 
is widely used to control malaria vectors, has also been detected in the breast 
milk of South African women (10).  The latter data pose questions regarding 
the safety of deltamethrin, as developmental neurotoxicity and other adverse 
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developmental effects are currently being studied in these susceptible 
populations (1).      
Adipose tissue is a lipophilic tissue that is metabolically active and 
essential for the proper maintenance of systemic energy balance.  
Adipogenesis requires a highly regulated cascade of transcription factors, 
including C/EBP family and Pparγ, which regulate the differentiation of 
preadipocytes to adipocytes (11).  Most recently, this cascade of transcription 
factors has been proven to be regulated by Nrf2, a well-defined transcription 
factor of oxidative stress (12,13). The three major functions of adipose tissue 
are lipid storage and mobilization, glucose homeostasis, and endocrine 
function, involving secretion of hormones, cytokines, and transcription factors 
(11,14).  Changes in the expression of transcription factors involved in 
adipocyte differentiation during development can lead to dysfunction in the 
metabolic and endocrine functions of white adipose tissue (WAT), as 
demonstrated by gene knock-down, knock-out, and induction studies (11,14).  
When characterizing deltamethrin as a safe pesticide, The World Health 
Organization (WHO) observed lower body weight gain in adult rats that were 
orally administered the pesticide, decreased mean fetal weights with a 
perinatal high dose of 10 mg/kg body weight, and a dose-related decrease in 
body weight of postnatal mice (15).  Despite increased research on the 
developmental toxicology of pyrethroids, to our knowledge, no studies have 
addressed whether exposure to pyrethroids during developmental stages 
affects adipose tissue development and homeostasis.  Therefore, the purpose 
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of this study was to address the potential metabolic effects of perinatal 
deltamethrin exposure in white adipose tissue, to address previously 
described changes in body weight during development.   
 
 
MATERIALS AND METHODS  
 Animals 
Eight week old female and male C57BL/6J mice purchased from 
Jackson Laboratory (Bar Harbor, ME) were used. Mice were maintained on a 
12:12 light/dark cycle with food and water available ad libitum. All procedures 
were conducted in accordance with the NIH Guide for Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee at Robert Wood Johnson Medical School.   
 Treatment 
10 week old female C57BL/6J mice were individually housed and 
mated with C57BL/6J males. Upon identification of a vaginal plug, males were 
removed and single-housed female mice were administered 0 (control), 1, or 3 
mg/kg body weight deltamethrin (ChemService, West Chester, PA), dissolved 
in corn oil and mixed with peanut butter (~ 100 mg; Skippy Creamy Peanut 
Butter) every 3 days throughout gestation and lactation as described 
previously (16-18).  Mice were monitored to ensure total consumption of the 
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treatment dose, which generally occurred within 10 min. This administration 
method reduces handling stress associated with injections during pregnancy 
and most closely mimics human oral exposure conditions (16,17). 
The dose selected in this study is 1/4 of the developmental NOAEL 
(19).  Unfortunately, the rapid metabolism of pyrethroids has made dose 
extrapolation difficult. There have been no comparative studies in rodent and 
humans to determine half-lives of the parent compound, but separate studies 
have presented the half-life of deltmethrin, in humans and rats, to appear to be 
in a similar range of several hours.  It should be noted that recent 
pharmacokinetic modeling in rats predicted that humans would experience a 
higher brain concentration of deltamethrin compared to rodents, most likely 
because humans do not have plasma carboxylesterase activity (20).   
The offspring were weaned at postnatal day (PND) 25, and once 
weaned; offspring received no additional exposure to deltamethrin.  The 5 
month time point was selected because tissues were being shared from a 
cohort from a study being conducted by Dr. Richardson’s group for the primary 
purpose of developmental deltamethrin effects on behavior.  Those cohorts 
had been assessed for neurobehavioral changes and 5 months was 
determined to be an appropriate time of necropsy for Dr. Richardson’s study.  
As 5 months represents adulthood and mature adipose tissue, white adipose 
tissue was evaluated for changes in expression of genes related to 
adipogenesis, lipid synthesis, glucose uptake, and inflammation. 
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Prior to sacrifice, blood glucose concentrations were obtained via tail 
vein nick and measured using a TRUEtrackTM glucometer.  Animals were not 
fasted prior to sacrifice.  Mice were sacrificed by CO2 inhalation followed by 
cardiac puncture for blood collection at 5 months of age. Blood was 
centrifuged at 14,000 × g for 10 min to obtain serum. White adipose tissue 
from the abdomen was removed and snap frozen in liquid nitrogen. Samples 
were stored at -80oC until shipment to University of Rhode Island on dry ice. 
Dosing of mice and sample collection was carried out by the laboratory of Dr. 
Jason Richardson at the University of Medicine and Dentistry of New Jersey, 
Piscataway, NJ.  
 RNA Extraction 
Perinatal exposure to deltamethrin causes postnatal behavioral 
changes in adult male, but not female, offspring (Richardson et al., submitted). 
For this reason, adult male mice were selected for the current investigation.  
Total RNA was isolated from 50-100 mg frozen WAT from the male 5 month 
cohort via homogenization in TrizolTM lysis buffer (Life Technologies, Grand 
Island, NY) followed by chloroform-isopropanol extraction. The RNA 
concentration was determined by measuring UV absorbance of the sample at 
260 nm using NanoDrop™ (Wilmington, DE) and RNA integrity was confirmed 
by the presence of distinct 18S and 28S bands using formaldehyde-agarose 
gel electrophoresis.   RNA samples were stored at -80°C until utilized.  
 Quantigene Plex 2.0 Assay  
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Total RNA was applied to the Quantigene Plex (Affymetrix, Santa Clara, 
CA) and hybridized overnight at 54˚C with specific mRNA capture beads and 
capture probes.  The following day, the samples were hybridized with pre-
amplifier and a biotinylated label probe for 1 h at 50˚C followed by application 
of streptavidin conjugated phycoerythrin detection probe for 30 min at room 
temperature. The plex was analyzed on a Luminex Bio-Plex 200 array reader 
with Luminex 100 xMAP technology (Austin, TX). mRNA expression was 
normalized to the Rpl13a housekeeping gene, which was not significantly 
different between treatment groups.  Only male gene expression in adipose 
tissue was determined in an attempt to reduce gender variability as a 
confounding factor 
 
qPCR mRNA Quantification  
qPCR was utilized measure the mRNA gene expression of important 
genes in WAT that were not available on the Quantigene Plex used.  Total 
RNA was utilized as a template to make complementary DNA via polymerase 
chain reaction (PCR) following the specified protocol for Transcriptor First 
Strand cDNA Synthesis Kit (Roche Applied Sciences Cat. #: 04897030001).  
The cDNA was amplified and quantified for gene expression levels using 
LightCycler 480® SYBR Green I Master chemistry (Roche Applied Sciences) 
for qPCR determination of Nrf2, Nqo1, and Gclc.  Rpl13a was used as the 
housekeeping gene for normalization.   
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 Statistical Analysis 
 Statistical analyses of data were performed using a one-way analysis of 
variance (ANOVA) and further analyzed by a Dunnett’s Test post hoc test to 
determine significant different between control and each treatment group.  P < 
0.05 was considered statistically significant.  Unless otherwise stated, all data 
were presented as mean ± SE of 9 animals (control) and 8 animals (1 mg/kg, 
3mg/kg doses).  Statistica v.9 (StatSoft, Tulsa, OK) was used for statistical 
analysis.   
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RESULTS  
 
Effect of developmental exposure on physiological parameters and the 
expression of genes related to glucose homeostasis in WAT 
The physiological data collected prior to necropsy showed no significant 
differences in the body weight (BW) between pups that were exposed to 
vehicle or deltamethrin during development (Fig. 1A), and blood glucose 
concentration was similar between both treatments compared to control (Fig. 
1B).  The expression of a predominant insulin-responsive gene and two 
essential glucose transporters in WAT were determined using Luminex 
100xMAP technology.  Figure 1C shows that there were some differences 
between the gene expression of insulin responsive genes and glucose 
transport genes, Irs-1, Glut4, and Glut2, in WAT.  Developmental deltamethrin 
(1 mg/kg) exposure decreased Glut4 (31%), and both deltamethrin doses 
significantly decreased Glut2 mRNA (83%, 82%).  No changes in Irs-1 mRNA 
expression were observed.  These data are supported by the blood glucose 
measurements that were also found to be unchanged with perinatal 
deltamethrin exposure.   
Effect of developmental deltamethrin exposure on expression of genes 
related to adipogenesis and lipogenesis in WAT 
 There were no significant differences in body weight between the male 
pups that were exposed to vehicle or deltamethrin during development at 5 
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months of age (Fig 1A), but because of the significant decrease in mRNA 
expression in glucose transport the primary functions of adipose tissue, 
development of adipocytes and lipid transport and metabolism should be 
described.  Expression levels of lipogeneic genes in WAT and the well 
described regulators of adipogenesis were determined using Luminex 
100xMAP technology.  Significant decreases in the expression of lipogenic 
genes Srebpf1 (28%), Acc-1 (44%), Fabp4 (19%), Cd36 (21%), Lpl (22%), and 
Scd-1 (22%) were observed in the 1mg/kg treatment group compared to 
control.  Furthermore, no changes in the expression of any of the lipogeneic 
genes measured were observed in the 3 mg/kg treatment group (Fig. 2A). The 
relative gene expression of adipogenesis regulators (Pparγ, Cebpα, and 
Cebpβ) is illustrated in Figure 2B.  Perinatal deltamethrin exposure (1 mg/kg) 
decreased Pparγ and Cebpα expression in WAT 28% and 32%, respectively, 
compared to vehicle controls.  Cebpβ expression in WAT was similar for all 
groups.  A potential further up-stream regulator of adipogenesis and lipid 
metabolism in adipose issue is Nrf2 (13,21).  Nrf2 and its target genes Nqo1 
and Gclc were measured by qPCR, using LightCycler 480® SYBR Green 
chemistry and instrumentation, and presented in Figure 2C.  Nrf2, Nqo1, and 
Gclc were all significantly down-regulated at the 1 mg/kg treatment. Nrf2 was 
decreased to 27%, Nqo1 13%, and Gclc 11% of the control.  The decreased 
mRNA of the down-stream target genes of Nrf2 suggests the decreased 
protein level or activity of Nrf2, which if decreased could potentially explain the 
down-regulation of gene expression by perinatal deltamethrin exposure.    
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Effect of developmental deltamethrin exposure on cytokine mRNA 
expression in WAT 
Tnf, Ccl-2, Cd11c, Fas/Tnf-R, Cd209e, and Il4 cytokine levels in WAT 
were measured in 5 month old male pups that were exposed to deltamethrin 
via perinatal exposure. Significant decreases in cytokine levels for both 
treatment groups were observed when compared to control group (Fig. 3).  Tnf 
levels decreased 47% in the 3 mg/kg treatment group, compared to the control 
group. Tnf expression was similar between control pups and pups exposed to 
the 1 mg/kg developmental deltamethrin dose. Cd11c expression was only 
decreased in the 3 mg/kg group by 66% compared to control. Tnf-R 
expression was markedly decreased 70% (1 mg deltamethrin/kg) and 75% (3 
mg deltamethrin/kg) when compared to the control group.   Cd209e levels 
were decreased to 39% of control in the 1 mg/kg treatment group, but were 
similar to controls in the 3 mg deltamethrin/kg group.  There were no 
significant differences in Ccl-2 and Il4 cytokine levels compared to the control 
in either the 1 mg/kg or 3 mg/kg treatment groups.        
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 DISCUSSION 
Deltamethrin and other pyrethroids have been established as safe 
pesticides based on data showing decreased toxicity in mammals from rapid 
metabolism to non-toxic or less-toxic forms of the parent compound (3).  Many 
pharmacokinetic and dynamic studies have elucidated that a portion of orally 
administered pyrethroids partition into fatty tissues, in which they persist for at 
least 3 weeks (3,22,23).  Deltamethrin can be detected  in the adipose tissue  
of rats with a half-life of 5-6 days (24), and is most persistent in the body fat of 
animal models (3).  The retention of these highly lipophilic pesticides in 
metabolically active adipose tissue should increase the spectrum of research 
from not only neurotoxicity, but to the possibility of metabolic effects of 
pyrethroid exposure, especially in susceptible populations.   In this study, we 
showed that developmental deltamethrin affects adipogenesis and lipid 
homeostasis at the transcriptional level, decreasing the expression of some 
genes in the offspring of dams exposed to 1 mg/kg every three days.  Previous 
toxicological studies noted non-dose-dependent reduction in body weight gain 
in adult rats and dogs following short-term exposure (0.1-10 mg/kg), and 
decreased fetal weight in rabbits at 16 mg/kg perinatal exposure (15).  In a 
reproductive study on deltamethrin using rats, Abdel-Khalik et al. (25) 
observed a significant dose-dependent difference (p<0.01) in mean fetal 
weights and retardation of fetal growth at all doses tested (1, 2.5, 5 mg/kg).  
These observations of retarded development of body mass correlate to the 
transcriptional down-regulation in gene expression for the major transcription 
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factors of adipogenesis, Pparγ and Cebpα, which regulate adipocyte 
development and maintain adipocyte phenotype through regulation of 
downstream targets Cd36, Lpl, and Glut4.  A significant down-regulation of 
cytokines excreted by WAT that are involved directly in the T-cell response 
(Tnf, Fas/Tnf-R, Cd209e), has a direct influence on the development of 
adipocytes.  Decreased levels of these cytokines, potentially may contribute to 
an altered primary immune response of dendritic cells (Cd209e), initiation of 
programmed cell-death by recruitment of caspase (Fas/Tnf-R), or alteration of 
macrophage Tnfα secretion, which could impact adipocyte differentiation and 
proliferation. The expression of fatty-acid uptake genes, Fabp4, Cd36, and Lpl, 
regulated by Pparγ, were down-regulated, consistent with an overall metabolic 
change in gene expression for the pathway.  The down-regulation of Srebp1c, 
a transcription factor abundant in WAT that regulates and maintains lipid 
homeostasis through downstream targets Acc-1 and Scd-1, contributes further 
to alterations in the metabolic state of WAT in the developing mice.  The 
reported non-monotonic dose-response of changes in gene expression cannot 
be explained by previous observations or our physiological findings.   
The physiological data herein describing cohorts of developmentally 
exposed male mice conflicts with previously reported toxicological 
observations for reproductive and developmental toxicity studies in rats, which 
reported significant changes in body weight and WAT mass (15).  No 
significant difference in body weight and liver weight was observed between 
vehicle and deltamethrin-treated groups in multiple cohorts of 4, 5, and 11-12 
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months of age male mice (data not shown).  However, the finding that 
developmental deltamethrin exposure increases locomotor activity may 
confound the interpretation of potential body weight changes and metabolic 
phenotypic changes (Richardson et al., personal communication), which is 
why the significant changes in regulators of adipogenesis and lipid metabolism 
at the mRNA level suggests potential underlying epigenetic effects.   
Little is known regarding the effect of deltamethrin on glucose 
homeostasis, metabolic, or immune response.  Our data suggest that 
developmental deltamethrin exposure had no marked effect on glucose 
homeostasis based on blood glucose concentrations, but significant changes 
in the relative gene expression of Glut4 and Glut2 in WAT are noted.  Glut4 is 
a major glucose transporter in WAT that if down-regulated will decrease the 
insulin-responsive uptake of glucose into the cells, but the significant down-
regulation of Glut2 at both treatment doses, major glucose transporter in the 
liver, has the potential to affect glucose transport between adipose tissue, 
plasma, and potentially liver.  A decrease in the glucose transport genes may 
alter the deposition of glucose. Early insulin-resistance has been linked to 
adipose tissue dysfunction (26) and decreased WAT expandability is 
associated with increased risk for diabetes or glucose intolerance (21,27,28).  
Thus, deltamethrin might affect the normal response to high-fat diet challenge 
or treatment with thiazolidinedones, which promote adipogenesis to improve 
insulin resistance.  
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The transcriptional down-regulation of genes essential for adipose 
development and lipid metabolism in offspring after perinatal exposure to 1 
mg/kg dose of deltamethrin provides data that supports the potential for 
metabolic effects of deltamethrin exposure during development with regard to 
WAT expandability.  Nrf2, normally known for its role in oxidative stress, has 
recently been shown to be a regulator of adipose development and function 
(12).  Nrf2 has been shown to be an upstream regulator of Pparγ and Cebpα, 
in which Nrf2 knock-out in MEF cells decreased lipid accumulation, decreased 
Pparγ and Cebpα expression at the protein, along with down-stream target 
genes (13).  Therefore, the decreased expression of Nrf2 and its target genes 
at the mRNA level can serve as initial evidence that Nrf2 may be involved in 
the gene expression changes related most specifically to the transcription 
factors Pparγ and Cebpα, and therefore, lead to changes in glucose and lipid 
homeostasis.  These significant changes in gene expression at the 
transcriptional level may correlate to an epigenetic regulation in the offspring 
that may eventually lead to altered responses of WAT to environmental 
toxicants (i.e. obesogens, endocrine disruptors) or changes in diet (i.e. high-fat 
diet), however these changes did not manifest in significant alteration in 
physiological parameters.  To summarize, perinatal deltamethrin exposure did 
not result in measurable changes in body weight in male offspring at 5 months 
of age, but did decrease the expression of some genes related to 
adipogenesis, lipogenesis, and inflammation in WAT that may potentially be 
under the regulation of alterations in Nrf2 activity. 
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FIGURE LEGENDS 
Figure 1.  Body weight was used to describe any potential metabolic effects of 
perinatal deltamethrin exposure, along with blood glucose concentration and mRNA 
gene expression of key factors in insulin response of WAT to describe potential 
effects on glucose homeostasis.  Body weights of 5 month old male mice were taken 
prior to sacrifice. (A) Average body weight (g) of each treatment group expressed as 
a mean BW ± SEM (n=6-7). (B) Blood glucose level taken at time of necropsy of 5 
mo. adult male mice expressed as a mean BG ± SEM (n=5-6).  mRNA gene 
expression data in white adipose tissue of 5 month old adult male mouse pups from 
dams exposed to 0, 1, or 3 mg delatmethrin/kg every three days during getation and 
lactation.  Total RNA was isolated from white adipose tissue and mRNA levels were 
quantified by Quantigene Plex 2.0 assay (Affymetrix).  All gene expression data were 
normalized to Rpl13a (no significant change in gene expression) and are expressed 
as mean ± SEM (n=8-9).  (A) Insulin responsive and glucose transport: Irs-1, Glut-4, 
Glut-2 mRNA expression. mRNA gene expression data in white adipose tissue of 5 
month old adult male mouse pups from dams exposed to 0, 1, or 3 mg 
deltamethrin/kg every three days during gestation and lactation. * and # represents 
statistical difference between control and treatment doses (p<0.05 and p<0.005, 
respectively).    
Figure 2.  mRNA gene expression data in white adipose tissue of 5 month old adult 
male mouse pups from dams exposed to 0, 1, or 3 mg deltamethrin/kg every three 
days during gestation and lactation. Total RNA was isolated from white adipose 
tissue and mRNA levels were quantified by Quantigene Plex 2.0 assay (Affymetrix).  
All gene expression data were normalized to Rpl13a (no significant change in gene 
expression) and are expressed as mean ± SEM (n=8-9). (A) Regulators of 
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B) Lipogenic 
genes:Srebp1, Acc-1, Fabp4, Cd36, Lpl, Scd-1 mRNA expression.  mRNA gene 
expression for Nrf2, Nqo1, and Gclc was quantified by Lightcycler 480 SYBR green 
qPCR method.  (C)  Nrf and target genes Nqo1 and Gclc mRNA expression.  *and # 
represents statistical difference between control and treatment doses (p<0.05 and 
p<0.005, respectively).          
Figure 3.  mRNA gene expression of relevant cytokines in white adipose tissue of 5 
month old adult male pups from dams exposed to 0, 1, or 3 mg deltamethrin/kg every 
three days during gestation and lactation. Total RNA was isolated from white adipose 
tissue and mRNA levels were quantified by Quantigene Plex 2.0 assay (Affymetrix).  
All gene expression data were normalized to Rpl13a (no significant change in gene 
expression) and are expressed as mean ± SEM (n=8-9) Cytokines: Tnf, Ccl-2, Cd11c, 
Fas/Tnf-R (M1 macrophage markers) and Cd209e (M2 macrophage marker). * and # 
represents statistical difference between control and treatment doses (p<0.05 and 
p<0.005, respectively).  
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Figure III-1.  
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Figure III-2.  
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Figure III-3.  
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CONCLUSION 
Obesity has previously been defined at the dysregulation of energy balance, in 
which nutrient intake exceeds energy expenditure; therefore excess nutrients 
are stored in WAT (Christodoulides et al., 2009).  The primary role of WAT is 
to store excess FFAs in the form of triglycerides, and because of this WAT is 
physiologically able to handle greater FFA and oxidative stress loads than 
other metabolically active tissues (Kusminski and Scherer, 2012).  Therefore, 
WAT is known for its expandability—which has been suggested to be directly 
related to the pathophysiology of diseases related to overall metabolic 
syndrome (Christodoulides, Lagathu, Sethi and Vidal-Puig, 2009).  AT 
expandability is recognized as an adaptive response to excess nutrient intake, 
thus preventing lipid deposition and toxicity in alternate organs (Rutkowski, 
Stern and Scherer, 2015).  Expandability can be considered through two 
mechanisms: hypertrophy and hyperplasia.  Hypertrophy is the expansion of 
fat mass due to an increase in adipocyte size, and hyperplasia is due to 
increased adipocyte number or differentiation (Rutkowski, Stern and Scherer, 
2015).  The relative turnover of mature adipocytes or induction of adipocyte 
differentiation in adults is considered low (Spalding et al., 2008).  Therefore, 
the effects of environmental exposures, Deltamethrin and BDE-99, and the 
beneficial effects of dietary restriction or CR on Nrf2 expression and WAT lipid 
metabolism can be summarized considering the changes in expandability of 
WAT.   
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Hyperplasia within AT can be considered directly related to the ability of pre-
adipocytes to differentiate to adipocytes.  Hyperplasia is essential for AT 
expandability, but because of low turnover may not be directly to human 
exposure models.  Therefore, much of the research considers obesity as being 
directly related to hypertrophy of adipocytes (La Merrill, Emond, Kim, Antignac, 
Le Bizec, Clement, Birnbaum and Barouki, 2013).  The two environmental 
chemicals presented in this dissertation support the importance of AT 
expandability and the potential chemical effects that can result in AT 
dysfunction due to hypertrophy.  MANUSCRIPT III demonstrated that 
regulation of WAT expandability can be altered during development.  
Deltamethrin significantly decreased adipogenic, lipogenic, and glucose 
uptake gene expression in adult mice exposed perinatally.  This did not result 
in a phenotypic change, but with a HFD-challenge could demonstrate the 
physiological relevance of inhibited AT expandability.  MANUSCRIPT II 
findings showed that the environmental compound BDE-99 can increase AT 
hypertrophy in vitro in both mice and humans.  This was demonstrated by no 
significant findings in AT differentiation, but a marked increase in lipogenic 
gene expression and lipid deposition in BDE-99 treated cells.  This manuscript 
supports previous findings and studies that identify compounds as obesogens 
(La Merrill, Emond, Kim, Antignac, Le Bizec, Clement, Birnbaum and Barouki, 
2013).  Lastly, MANUSCRIPT I exemplified CR as an effective treatment to 
decrease WAT mass and lipid content through mechanisms directly related to 
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the antioxidant response in order to achieve homeostasis where energy intake 
does not exceed energy expenditure.   
Most significantly, all three manuscripts support a novel role for Nrf2 regulation 
in WAT expandability and lipid homeostasis.  Environmental exposures of 
deltamethrin and BDE-99 that predispose or contribute to AT hypertrophy, 
respectively, were correlated to decreased Nrf2 gene expression.  While, AT 
homeostasis achieved by CR was shown to induce Nrf2 gene expression and 
key pathways of lipid metabolism were demonstrated to be Nrf2-dependent.  
This dissertation supports the role of Nrf2 to achieve AT homeostasis, 
maintain lipid homeostasis, and prevent against AT hypertrophy that can result 
in obesity and metabolic syndrome.     
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